header logo image


Page 22«..10..21222324..30..»

Archive for the ‘Molecular Genetics’ Category

Scientists reveal the most extensive genetic map of cancers ever made – The Economist

Monday, February 10th, 2020

Feb 8th 2020

PERHAPS MORE than any other, cancer is seen as a disease of genes gone wrong. So, as genetic-sequencing technology has become cheaper and faster, cancer scientists are using it to check which changes to genes cause tumours to spread.

The latest insights from one group, the international Pan-Cancer Analysis of Whole Genomes (PCAWG), are revealed this week in Nature. In an analysis of the full genomes of 2,658 samples of 38 types of tumour taken from the bladder to the brain, the researchers give a blow-by-blow account of how a series of genetic mutations can turn normal cells into runaway clones. It provides the most comprehensive analysis yet of where to find this damaging disruption to DNA and, by unpicking the genetics of what makes cancer tick, just how hard it will be to tame.

For each of the cancer samples, the team produced a read-out of the tumour genomethe 3bn or so individual DNA lettersand compared it with the genome sequences of healthy cells taken from the same patients. In this way they could look for the genetic signatures of the cancer cells, where specific mutations had warped the genetic information.

Most mutations in the genome are harmless. But driver mutations, where genetic changes cause a cell to multiply more easily and faster than other cells, can trigger tumour growth. Many driver mutations have been found over the past decade and a handful have been translated into new medicines. In a fifth of breast cancers (pictured), for example, a driver mutation in the gene HER2 makes cells produce more of a protein on their surface that encourages them to grow and divide out of control. A series of drugs, including Herceptin, target this protein, and lead to significantly improved survival rates. The same HER2 mutation also appears in some lung cancers, raising hopes that similar therapies could work against that disease.

The problem is that most cancers have multiple driver mutations. Indeed, the PCAWG work found that on average each cancer genome carried four or five. And with some clever genetic archaeology they also found that some driver mutations can occur years before symptoms appear.

To discover this, researchers used a new concept called molecular time to reconstruct the cellular evolution of tumour cells. By comparing the DNA of cells within tumours, the researchers could place mutations in chronological order based on how many cells they appeared in. Earlier mutations occur more frequently. For example, driver mutations in a gene called TP53 were found to have originated at least 15 years before diagnosis in types of ovarian cancer, and at least five years before in types of colorectal and pancreatic cancer. Driver mutations in a gene called CDKN2A were found to have occurred in some lung cancers more than five years before diagnosis. In theory, that provides a window in which to find people at risk of developing these diseases, and perhaps prevent the cancer ever appearing.

The new study closes down talk that significant numbers of unknown driver mutations could lurk in the relatively unexplored regions of the human genome. One such driver mutation in non-coding DNA was found in 2013a mutation in the TERT gene across many different cancer types. To check for more like this, the consortium sequenced and analysed all the DNA letters of these non-coding regions (which account for 98% of human DNA) for the first time. They found that non-TERT driver mutations occurred at a rate of less than one per 100 tumours in these regions.

Peter Campbell of the Wellcome Sanger Institute in Cambridge, Britain, and a member of the PCAWG consortium, says an important contribution of the study is that by sequencing so many tumours it has raised the number of patients in whom a genetic contribution to their cancer can be identified from less than 70% to 95%. The goal, he says, is for genome sequencing of tumours to become routine. Efforts to introduce this are under way in some countries, including Britain, the Netherlands and South Korea, he adds.

Insights are all very well, but what about cold, hard clinical progress? Turning genome sequences into meaningful predictors of cancer will require comparisons between samples from tens of thousands of patients, say the researchers, along with data on their treatments and survival rates. Processing this would be beyond the reach of any single organisation. Instead, a follow-up project is planned that includes national funding agencies, charities and corporate partners from more than a dozen countries around the world. It aims to link full sequences of 200,000 cancer patients to their clinical data by 2025.

This article appeared in the Science and technology section of the print edition under the headline "Scientists reveal the most extensive genetic map of cancers ever made"

Read the original:
Scientists reveal the most extensive genetic map of cancers ever made - The Economist

Read More...

Coronavirus: Meet the Scottish doctor working to create life-saving vaccine – Scotland on Sunday

Monday, February 10th, 2020

The Scottish scientist in the frontline of the battle against the deadly coronavirus is warning the need for a vaccine is even more critical with more than 31,000 confirmed cases and around 630 deaths.

Dr Kate Broderick, is working round the clock with her team of researchers at the pharmaceutical company Inovio in San Diego to develop a jab in just six months.

The 42-year-old, who is originally from Dunfermline, and has been living in California for 20 years, says the aim is to make a vaccine faster than theyve made any other in our history.

Broderick has helped create successful vaccines for ebola, zika, lassa fever and Mers (Middle East Respiratory Syndrome) moving from Glasgow to develop her work in molecular genetics.

She first read about the coronavirus outbreak on Hogmanay and saw that the World Health Organisation had reported a couple of cases.

From there the Chinese authorities published the DNA sequence online which was the trigger for Broderick and her team to start working on a new vaccine.

She said: Seeing it online was like 100 per cent confirmation that this was a new virus but even before that from the disease symptoms it wasnt fitting into any particular box.

So, we already suspected that this was something new.

We downloaded the sequences and the first stage of our development is done on a computer which is why our technology at Novio allows us to go so far.

We ran the sequences through a computer algorithm and three hours later we actually had a full design for the vaccine and the next day we were able to put that into manufacturing.

She added: Its definitely 100 per cent a race against the clock were working here 24/7 and thats not an exaggeration to get this thing out.

What were trying to do here is make a vaccine faster than weve ever made any other vaccine in our history.

Our fastest in the past was seven months from sequence to patient and that was for the Zika outbreak where kids were being born with these terrible neurological deficits and we really sprang into action there.

We got the viral sequence and we got it tested in humans within seven months and we were so proud of that and here for the novel coronavirus were trying to do it significantly faster than that.

We need international support and I think were seeing that in the scientific community.

Theres a lot of organisations working together but its absolutely a race against time.

The UK government announced earlier this week that it has pledged 20 million to develop new vaccines to combat the worlds deadliest diseases, amid concerns over the novel coronavirus, 2019-nCoV.

Dr Broderick welcomed the funding which will go to the Coalition for Epidemic Preparedness Innovations (CEPI), originally formed in response to the Ebola epidemic in West Africa.

She added: Thats what we need now funding to support this work.

We have to follow all the established protocols and work with the authorities thats absolutely critical.

So, all we would do first is a phase one clinical trial which we plan to do early summer.

Thats testing it on completely healthy people just to get a read-out of the fact the vaccine is safe and its doing what we hope its going to do.

We hope to roll that out in the US in the early summer and well also be working with our colleagues in China to do similar kinds of trials there with an eye to discussing with the Chinese authorities to get the vaccine out to people who need it as soon as its available.

Dr Broderick has retained her Scottish accent having gone to St Columbas High School in Dunfermline before studying genetics at the University of Glasgow, where she also completed her PhD.

Her father was a physicist, her mother a therapist, one of her sisters is a nurse and the other is a social worker.

She met her husband, Steve, in California, and 20 years on is still there. She has two children, Rory, aged eight, and four-year-old Isla.

She said: Every single day almost someone will ask me if Im here on vacation and Ill say no Ive been here for 20 years.

I come back to Scotland at least once a year and my whole family are still in Scotland and I feel very, very Scottish.

Im proud of my adopted home in California but I very much consider myself Scottish.

Here is the original post:
Coronavirus: Meet the Scottish doctor working to create life-saving vaccine - Scotland on Sunday

Read More...

Image of the Month: Human breast epithelial cells – Baylor College of Medicine News

Monday, February 10th, 2020

Epithelial cells line the lobules (small lobes) and terminal ducts of the breast and carry out the important function of making milk. Cancer scientists, such as Dr. Chonghui Cheng at Baylor College of Medicine, have great interest in these cells because they can transform into cancer cells giving rise to carcinomas, which represent the vast majority of breast cancers.

The Cheng lab investigates how RNA regulation controls cellular processes in normal biology and in the context of cancer, including metastasis. Using molecular biology, genomics and bioinformatics approaches in conjunction with genetic models and patient samples, the Cheng lab currently focuses on the regulation of breast cancer metastasis driven by alternative splicing.

Dr. Cheng is an associate professor in the Lester and Sue Smith Breast Center and the Departments of Molecular and Human Genetics and of Molecular and Cellular Biology at Baylor. She also is a member of the Dan L Duncan Comprehensive Cancer Center.

By Ana Mara Rodrguez, Ph.D.

Originally posted here:
Image of the Month: Human breast epithelial cells - Baylor College of Medicine News

Read More...

Advanced diagnostic methods needed to prevent, treat cancer – The Tribune

Monday, February 10th, 2020

Tribune News Service

Bathinda, February 4

To commemorate World Cancer Day, Central University of Punjab (CUP) on Tuesday organised lectures on topic, Cancer Prevention and Awareness, on February 3.

The programme was organised by the Departments of Biochemistry, Zoology and Human Genetics & Molecular Medicine under the leadership of Vice-Chancellor Prof K Kohli. Eminent oncologists Dr Praveen Bansal, Director, Baba Farid University of Health Science (BFUHS), Faridkot, and cancer immunologist Dr Sunil Arora, cancer immunologist, PGIMER, Chandigarh, were the guest speakers.

The speakers highlighted the need for lifestyle modifications to reduce the risk of cancer. Besides faculty members, non-teaching employees, over 300 students and research scholars took part in the event.

Dr Aklank Jain, a cancer biologist from the Department of Zoology, welcomed the guest speakers and introduced the programme theme. He said: There is a need for advanced cancer diagnostic methods to prevent and treat cancer.

Dr Parveen Bansal defined cancer as malignant growth caused due to uncontrolled division of cells. He said spices, vegetables and fruits kept diseases at bay. He emphasised practising asans such as upavasa, dinacharya and ritucharya in daily life to stay fit and healthy.

Dr Sunil Arora said it was essential to study tumour microenvironment to identify the growth and development of cancer cells. He said additional research was needed to study the origin and chemoresistance of cancer cells. Cancer can be cured by targeting the tumour microenvironment and by strengthening the immune system, Dr Sunil said.

Dr Shashank Kumar, cancer biochemist from the Department of Biochemistry, CUP, said according to the Indian Council of Medical Research (ICMR) data, around 1.5 lakh new breast cancer cases occurred annually in the country. Stage 0 breast cancer is the earliest form of breast cancer and due to the absence of symptoms, it is hard to detect, he said. Dr Shashank said the periodic physical examination of breast by self or a trained health worker might help detect cancer early.

Dr Sabyasachi Senapati, human geneticist from the Department of Human Genetics & Molecular Medicine, CUP, said: Appropriate genetic tests for early diagnosis and preventive therapies for some forms of familial breast, prostate, uterine, colorectal, liver and ovarian cancer can reduce the risk of cancer by up to 40%. The Department of Health Research and the ICMR are creating awareness on the disease through several projects.

During the programme, university students presented a thematic poster. A nukkad natak to educate public about cancer prevention was staged by students.

Read more from the original source:
Advanced diagnostic methods needed to prevent, treat cancer - The Tribune

Read More...

Research Roundup: CRISPR-based cancer therapy, tanning studies, immigration and deportation – The Stanford Daily

Monday, February 10th, 2020

Each week, The Dailys Science & Tech section produces a roundup of the most exciting and influential research happening on campus or otherwise related to Stanford. Heres our digest for the week of Feb. 2 Feb. 8.

CRISPR-based cancer therapy shows promise

A new FDA-approved cancer therapy uses the gene-editing technology Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) to enhance T-cells, a type of immune cell, in order to better fight cancer, a study published on Feb. 6 in Science found.

Lets say normally, theres a T-cell thats involved in an allergic reaction to pollen, genetics and dermatology professor Howard Chang told Stanford Medicines blog SCOPE. We can use CRISPR to alter the cell so that it doesnt react to pollen anymore, and instead, only fights cancer.

The researchers goal was to introduce three gene edits to T-cells, then reintroduce edited T-cells back into the patient. The gene edits would rid T-cells of their natural receptors and increase their immune activity to actively fight cancer. After three months, researchers took edited T-cell samples from patients to analyze their molecular characteristics.

If you think of all of these edited T-cells like theyre in a horse race, analyzing these cells is like being able to see which horse wins the race, but also that horses speed, gait and all of the critical details that make that horse the best, Chang told Stanford Medicines blog SCOPE.

The findings suggest the therapy is safe, and further studies will need to be performed in future human clinical trials.

Industry-backed studies show bias favoring indoor tanning

Studies on indoor tanning that are financially backed by the tanning industry are more likely to promote benefits and dismiss risks compared to studies without financial support, an investigation published on Feb. 4 in the British Medical Journal found.

The association is quite striking, dermatology professor Eleni Linos told Stanford Medicine News. We need scientific data to be independent of industry influence. I am concerned that funding sources may influence the conclusions of these papers.

The researchers analyzed 691 journal articles referencing indoor tanning and found that 50 had industry backing. 78% of articles with industry backing portrayed indoor tanning in a positive light, compared to 4% of articles without industry backing.

This is the first study to examine conflict of interest in indoor tanning literature, and it echoes whats been said about the influence of the tobacco and sugar industries on science, Linos told Stanford Medicine News. Researchers, public health experts and members of the general public should be aware of and account for industry funding when assessing the evidence related to the risks and benefits of indoor tanning.

Immigrants who obtain legal status might still fear deportation

Immigrants might continue to fear deportation even after receiving documentation, a study published on Jan. 29 in Law & Society Review found.

Documentation is hardly a shield from deportation fears, sociology assistant professor Asad Asad told Stanford News. Documentation affords some protection from deportation, but it can also heighten fears since the bureaucracies that document immigrants have a greater perceived ability to surveil and expel them.

Between 2013 to 2015, he conducted extensive interviews with 50 undocumented and documented immigrants living in the Dallas metropolitan area to learn about their everyday lives.

Some undocumented migrants may be chilled out of legalization opportunities in an attempt to maintain a sense of invisibility to a system they view as primarily punitive, Asad told Stanford News. If fears of deportation lead immigrants to pass up rare opportunities for legal status in their search for invisibility from a system they view as unforgiving, they and their U.S.-citizen children may face restricted opportunities for promoting their long-term well-being in this country.

Contact Derek Chen at derekc8 at stanford.edu.

More here:
Research Roundup: CRISPR-based cancer therapy, tanning studies, immigration and deportation - The Stanford Daily

Read More...

Molecular Diagnostics Industry Report, 2020 to 2026 – Analysis by Product, Technology, Application, End-user and Region – PRNewswire

Saturday, February 8th, 2020

DUBLIN, Feb. 7, 2020 /PRNewswire/ -- The "Molecular Diagnostics Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The global molecular diagnostics global market is estimated to reach $18,668.9 million by 2026 growing at a high single-digit CAGR from 2019 to 2026.

Among the overall molecular diagnostic market is increasing prevalence of different types of cancers, infectious diseases, genetic disorders and other diseases, increasing awareness in personalized medicine and companion diagnostics and also growth in the point of care testing and sequencing-based tests and other molecular techniques.

Molecular diagnostics plays a pivotal role in the evaluation of the disease and for the effective response for specific therapy. However, the complex regulations for the approval of molecular diagnostic tests, availability of competing/alternative technologies, high cost of the tests, and also a shortage of technical experts are some of the restrains for the growth of the molecular diagnostics market.

Segment Highlights

The molecular diagnostics global market is segmented based on product, technology, application and end-users.

The product market is further categorized into instruments, consumables and software and services. As per research estimations, the consumable global market commanded the largest revenue in 2019 and is projected to grow at double-digit CAGR from 2019 to 2026.

The molecular diagnostics global market by technology is divided into PCR, microarray and microfluidics, isothermal nucleic acid amplification tests, in-situ hybridization, NGS and other technologies. PCR accounted for the largest revenue in 2019 and is expected to grow at a double-digit CAGR from 2019 to 2026 due to low cost and is a common and indispensable technique used for diagnosis when compared to other instruments such as NGS and also due to technological advancements in PCR and their subtypes such as digital droplet PCR with precise and highly sensible results.

The molecular diagnostics by application market is classified into infectious diseases, oncology, genetic testing, transplantation, blood screening and other diseases such as metabolic disorders and diseases associated with the central nervous system. The largest revenue was contributed by infectious diseases segment in 2019 and this market is expected to grow at a high single-digit CAGR from 2019 to 2026 due to high incidence of bacterial and viral infections.

Infectious diseases are further segmented into bacterial, viral and other diseases. The viral diseases commanded the largest revenue in 2019 and the market is expected to grow at a strong double-digit CAGR from 2019 to 2026. Viral diseases are further segmented into HIV, hepatitis, HPV, influenza and other viral infections. Among these, HIV accounted for the largest revenue in 2019 and is expected to grow at a double-digit CAGR from 2019 to 2026.

The bacterial diseases are sub-segmented into sexually transmitted diseases (STD) caused by bacteria, hospital acquired infections, tuberculosis and other diseases such as sepsis, pneumonia and meningitis, etc. Sexually transmitted disease accounted for the largest revenue in 2019 and is expected to grow at high single-digit CAGR from 2019 to 2026. The growth is attributed to the increased awareness about the molecular based kits available for the diagnoses of STDs and also increases in the prevalence.

Under genetic testing segment the market is segmented into NIPT, cystic fibrosis and other genetic testing, among them NIPT commanded the largest revenue in 2019 and is expected to grow at a double digit CAGR from 2019 to 2026 as NIPT provides a safer alternative to invasive tests and it analyzes fetal cell-free DNA (cfDNA) from the mother's circulation, making early detection of genetic disorders such as Down syndrome and other chromosomal aberrations easier.

Based on the type of cancer, the oncology market is segmented into lung, breast, colorectal, prostate, ovarian, melanoma, ovarian and other cancers. The largest revenue under oncology was accounted for by colorectal cancer with the revenue in 2019 and breast cancer is expected to grow at double-digit CAGR from 2019 to 2026.

Based on the cancer care, the oncology segment is subdivided into early screening, companion diagnostics, prognosis and recurrence. Early screening contributed for the largest revenue in 2019 and companion diagnostics is expected to grow at double-digit CAGR from 2019 to 2026. Further, the transplantation market is segmented into kidney, heart and other transplantation such as lung and pancreatic transplantation. Among them, kidney transplantation commanded the largest revenue in 2019.

Molecular diagnostics end-users market is segmented into hospitals, clinical/centralized laboratories, academics and research and other end users. Clinical/centralized laboratories accounted for the largest revenue due to the rapid adoption of technology and economies of scale in testing a large number of samples collected from affiliated hospitals.

Geographical wise, North America region commanded the largest revenue in 2019 and is expected to grow at a mid-single-digit CAGR from 2019 to 2026 owing to the high demand for early detection, treatment selection and prevention of diseases with advanced technology due to diseases associated with the lifestyle. However, the Asia-pacific region is expected to grow at an early teen CAGR from 2019 to 2026 attributing to increasing awareness of the molecular based test for the better outcome.

Competitive Landscape

The molecular diagnostics global market is a competitive market and all the existing players in this market are involved in developing new and advanced molecular based techniques for diagnosis to maintain their market shares and also acquiring companies for product expansion.

Some of the key players in molecular diagnostics global market are Abbott Laboratories (U.S.), F.Hoffmann-LA Roche AG (Switzerland), BioMerieux (France), Qiagen (Netherlands) Exact Sciences (U.S.), Grifols (Spain), Danaher Corporation (U.S.), Hologic, Inc. (U.S.), and Myriad Genetics, Inc. (U.S.)

Key Topics Covered

1 Executive Summary

2 Introduction

3 Market Analysis3.1 Introduction3.2 Market Segmentation3.3 Factors Influencing Market3.3.1 Drivers and Opportunity3.3.1.1 Increasing Incidence of Infectious Diseases3.3.1.2 Rising Incidence of Cancer and Non-Infectious Diseases3.3.1.3 Technological Advancements3.3.1.4 Favorable Reimbursements3.3.1.5 Investment by Major Players3.3.2 Restraints and Threats3.3.2.1 Lack of Skilled Professionals3.3.2.2 High Cost of Molecular Diagnostics Products3.3.2.3 Lack of Standardization of the Molecular Diagnostics Test3.3.2.4 Stringent and Time-Consuming Regulatory Issues3.3.2.5 Lack of Reproducibility and Repeatability3.3.2.6 Biochemical and Alternative Tests3.4 Market Share Analysis3.4.1 Molecular Diagnostics Global Market Share Analysis3.4.2 Molecular Diagnostics In Infectious Diseases Market Share3.5 Regulatory Affairs3.5.1 U.S.3.5.2 Europe3.5.3 China3.5.4 India3.5.5 Japan3.5.6 Australia3.5.7 South Korea3.6 Reimbursement Scenario3.7 Clinical Trials3.7.1 Ctdna Clinical Trials3.7.2 Cfdna Clinical Trials3.7.3 Circulating Tumor Cells3.7.4 Companion Diagnostics3.8 Latest and Upcoming Products3.9 Porter's Five Force Analysis3.10 Funding Scenario

4 Market Sizing4.1 U.S.Cancer Care Market Sizing Information4.1.1 Oncology Testing4.1.1.1 Early Screening4.1.1.2 Companion Diagnostics4.1.1.3 Prognosis Monitoring4.1.1.4 Recurrence Monitoring4.1.2 Non-Invasive Prenatal Screening (NIPT)4.1.3 Transplantation Diagnostics

5 Molecular Diagnostics Global Market, by Products5.1 Introduction5.2 Instruments5.3 Consumables5.4 Software and Services

6 Molecular Diagnostics Global Market by Technology6.1 Introduction6.2 PCR6.3 Microfluidics and Microarray6.4 Isothermal Nucleic Acid Amplification Technology (INAAT)6.5 In-Situ Hybridization6.6 Next Generation Sequencing (NGS)6.7 Others

7 Molecular Diagnostics Global Market, by Application7.1 Introduction7.2 Infectious Diseases7.2.1 Bacterial Diseases7.2.1.1 Sexually Transmitted Diseases7.2.1.2 Hospital Acquired Infections7.2.1.3 Tuberculosis7.2.1.4 Others7.2.2 Viral Diseases7.2.2.1 Hiv7.2.2.2 Hepatitis7.2.2.3 Influenza7.2.2.4 Human Papiloma Virus (HPV)7.2.2.5 Other Viral Diseases7.2.3 Other Infectious Diseases7.3 Genetic Testing7.3.1 Non-Invasive Prenatal Testing (NIPT)7.3.2 Cystic Fibrosis7.3.3 Other Genetic Diseases7.4 Oncology Testing7.4.1 Cancer Types7.4.1.1 Introduction7.4.1.2 Lung Cancer7.4.1.3 Breast Cancer7.4.1.4 Colorectal Cancer7.4.1.5 Prostate Cancer7.4.1.6 Melanoma7.4.1.7 Ovarian Cancer7.4.1.8 Others7.4.2 Cancer Care7.4.2.1 Introduction7.4.2.2 Early Screening7.4.2.3 Companion Diagnostics7.4.2.4 Prognosis Monitoring7.4.2.5 Recurrence Monitoring7.5 Transplantation7.5.1 Kidney Transplantation7.5.2 Heart Transplantation7.5.3 Other Transplantation7.6 Blood Screening7.7 Other Diseases

8 Molecular Diagnostics Global Market, by End Users8.1 Introduction8.2 Hospitals8.3 Clinical/Centralized Laboratories8.4 Academic and Research8.5 Others

9 Molecular Diagnostics Global Market, by Region9.1 Introduction9.2 North America9.2.1 U.S.9.2.2 Rest of North America9.3 Europe9.3.1 France9.3.2 Germany9.3.3 Italy9.3.4 Rest of Europe9.4 Asia-Pacific Region9.4.1 China9.4.2 India9.4.3 Japan9.4.4 Rest of Asia-Pacific9.5 Rest of the World9.5.1 Brazil9.5.2 Rest of Latin America9.5.3 Middle East and Others

10 Competitive Landscape10.1 Introduction10.2 Approvals10.3 Collaborations10.4 Acquisitions10.5 New Product Launches10.6 Others

11 Major Companies11.1 Abbott Laboratories11.1.1 Overview11.1.2 Financials11.1.3 Product Portfolio11.1.4 Key Developments11.1.5 Business Strategy11.1.6 SWOT Analysis11.2 Becton, Dickinson and Company11.3 BioMerieux11.4 Danaher Corporation11.5 Exact Sciences Corporation11.6 Grifols, S.A.11.7 Hologic, Inc.11.8 Myriad Genetics, Inc.11.9 Qiagen N.V.11.10 F. Hoffmann-La Roche Ltd.

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/47ly96

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Originally posted here:
Molecular Diagnostics Industry Report, 2020 to 2026 - Analysis by Product, Technology, Application, End-user and Region - PRNewswire

Read More...

New Light on the Genetic Relationship Between Three Mood Disorders – Technology Networks

Saturday, February 8th, 2020

Researchers shed new light on the genetic relationship between three mood disorders associated with depressionmajor depression and bipolar disorder types 1 and 2, in a newstudyin the journalBiological Psychiatry, published by Elsevier.

The clearest findings are a genetic distinction between type 1 bipolar and type 2 bipolar, and the greater similarity of type 2 bipolar to major depressive disorder, said first author Jonathan Coleman, PhD, a statistical geneticist and postdoctoral fellow in the lab of senior author Gerome Breen, PhD at the Institute of Psychiatry, Neuroscience, and Psychology at Kings College London, UK.

Both types of bipolar disorder used to be referred to as manic-depressive disorder. Mania is a behavioral state associated with behavioral activation, euphoric or irritable mood, reduced need for sleep, impulsive behavior, impaired judgement, racing disorganized thoughts, impulsive behaviors, and frequently strongly held false beliefs (delusions) or hallucinations. Bipolar disorder type 1 is associated with mania and depression, while bipolar 2 is predominately associated with depression marked by mild symptoms reminiscent of mania, called hypomania.

The insights came from several extremely large datasets analyzed together. For their meta-analysis, Coleman, Breen and their co-authors combined genome-wide association studies from three large datasets of people with major depression and bipolar disorder to evaluate shared and distinct molecular genetic associations. Most of the data came from the large international Psychiatric Genomics Consortium. Additional data came from the UK Biobank, a major health resource established by the Wellcome Trust, and the online genetic service platform, 23andMe.

There are significant racial and ethnic differences in the findings from genome-wide association studies (GWAS). The findings of this study pertain only to people of European ancestry and findings might be different in other groups.

The authors also report that the genetic risk for these disorders was predictive of other traits as well. For example, the genetic risk for bipolar disorder was correlated with more educational attainment, while the heritable risk for major depressive disorder was associated with less education.

In the mouse brain, the authors also mapped the genetic risk for these disorders on to particular brain cell types using a sophisticated analytic strategy building on the pattern of genes expressed. They implicated serotonin neurons in the risk for both depression and bipolar disorder, while bipolar disorder distinctively involved GABA and glutamate neurons (nerve cell types also implicated in schizophrenia).

We have long known that mood disorders are highly heterogeneous and the boundaries between types of mood disorders are often difficult to define clinically, said John Krystal, MD, editor ofBiological Psychiatry. This new study suggests that there are aspects of genetic risk, and presumably brain function, that link forms of mood disorders, but there are also distinctions that may shed light on subtypes of depression that may have important implications for treatment.

Ultimately, the researchers want to develop clinical tools to help predict if a first episode of depression is likely to persist as a disorder or progress into bipolar disorder. Genetic data wont ever replace clinical insight, but it might be a useful addition to clinical models, said Coleman.

Reference:Coleman et al. (2019). The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls. Biological Psychiatry. DOI: 10.1016/j.biopsych.2019.10.015.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the original post here:
New Light on the Genetic Relationship Between Three Mood Disorders - Technology Networks

Read More...

Gerald Fink awarded the Genetic Society of America’s Thomas Hunt Morgan Medal – MIT News

Saturday, February 8th, 2020

Gerald R. Fink,Whitehead Institute founding member and former director and professor of molecular genetics in the MIT Department of Biology, has been awarded the 2020 Thomas Hunt Morgan Medal, bestowed by the Genetics Society of America (GSA). The award recognizes a distinguished scientist who has a lifetime achievement in the field of genetics and a strong history as a mentor to fellow geneticists. TheGSA is an international community of more than 5,000 scientists who advance the field of genetics.

Fink, who is also the Herman and Margaret Sokol Professor at Whitehead Institute, is a former GSA president and the 1982 recipient of the GSA Medal. In honoring him with the Thomas Hunt Morgan Medal, GSA is recognizing Finks discovery of principles central to genome organization and regulation in eukaryotic cells.

This year, the Morgan Medal will also be awarded to David Botstein, chief scientific officer for Calico Labs and professor emeritus of molecular biology at the Lewis-Sigler Institute for Integrative Genomics at Princeton University, in recognition of his multiple contributions to genetics, including the collaborative development of methods for defining genetic pathways, mapping genomes, and analyzing gene expression.

These awards to Gerry and David are richly deserved and I am so pleased they are being honored together, says Whitehead Institute DirectorDavid Page. Gerry Fink has fundamentally changed the way researchers approach biological problems, and his many discoveries have significantly shaped modern science. David Botstein has helped drive modern genetics, establishing the ground rules for human genetic mapping. Page has worked closely with both men: beginning his research career as an investigator in Botsteins lab, and collaborating with Fink for more than three decades at Whitehead Institute.

The medals will be formally presented to Fink and Botstein at the Allied Genetics Conference in April.

More here:
Gerald Fink awarded the Genetic Society of America's Thomas Hunt Morgan Medal - MIT News

Read More...

The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs – Yahoo Finance

Saturday, February 8th, 2020

The following is a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech stocks that hit 52-week highsFeb. 5.)

Down In The Dumps

(Biotech stocks that hit 52-week lows Feb. 5.)

See also: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Stocks In Focus Sanofi's Multiple Sclerosis Drug Aces Midstage Trial; Q4 Sales, Net Income Rise

Sanofi SA (NASDAQ: SNY) said a Phase 2b study that evaluated its investigational BTK inhibitor SAR442168 for multiple sclerosis met the primary endpoint, with the candidate significantly reducing disease activity associated with multiple sclerosis. The candidate was also found to be safe and well-tolerated.

Separately, the company released financial results thatshowed 6.8% net sales growth for the fourth quarter, driven by Dupixent and vaccines, and 253.5% net income growth. The company said it expects 2020 business EPS to grow 5% at constant currency.

Tonix To Stop Enrollment For Late-Stage Study Of PTSD Drug

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) said it has decided to stop enrollment in the Phase 3 study dubbed RECOVERY that evaluated its Tonmya 5.6mg in treating post-traumatic stress disorder, following interim analysis of data by the Independent Data Monitoring Committee.

The IDMC sought stoppage of the trial for futility as it believed the experimental drug is unlikely to demonstrate a significant improvement in the primary endpoint of overall change from baseline in the severity of PTSD symptoms between the treatment and control arm.

The shares were plunging 59.91% to 68cents in premarket trading Thursday.

Arrowhead Reports Positive Mid-Phase Results For 2 Cardiometabolic Drug Candidates

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced positive interim results from ongoing Phase 1/2a studies of its two RNAi-based cardiometabolic candidates: ARO-APOC3, which is being evaluated for severe hypertriglyceridemia, and ARO-ANG3, whichbeing evaluated for dyslipidemias and metabolic diseases.

The company also released fourth-quarter results, showing a sales decline of 15% to $29.46 million and a loss of 3 cents. Analysts estimated a loss of 1 cent per share for the quarter.

The stock was trading 7.5% higher to $47 in Thursday's premarket session.

Earnings

Misonix Inc (NASDAQ: MSON) reported 17.3% revenue growth on a pro forma basis for its fiscal year second quarter, and its net loss widened year-over-year. The company reiterated its fiscal year 2020 outlook for revenue growth in excess of 20% and gross margins of about 70%.

View more earnings on IBB

The stock rose 5.97% to $19 in after-hours trading.

Cardiovascular Systems Inc (NASDAQ: CSII) reported a wider-than-expected seond-quarter loss, while revenueclimbed 13.5%. The company raised the low end of its 2020 revenue guidance.

The stock shed 1.94% to $44 in after-hours trading.

Offerings

Applied Genetic Technologies Corp (NASDAQ: AGTC) said it has commenced an underwritten public offering of 6 million shares of its common stock. All the shares are being offered by the company.

The stock slipped 9.70% to $6.33 in after-hours trading.

On The Radar Clinical Readouts

Jounce Therapeutics Inc (NASDAQ: JNCE) will present at the ASCO-SITC Symposium Phase 1/2 data for vopratelimab, codenamed JTX-2011, in solid tumors.

Earnings

IPO

Beam Therapeutics said it has priced its upsized initial public offeringof 10.59 million shares at $17 per share, at the upper end of the estimated price range of $15-$17. The shares of the company, which is engaged in developing therapies based on single-base gene editing, will begin trading on the Nasdaq under the ticker symbol "BEAM."

Contract research organization PPD priced its 60-million share IPO at $27 compared to the initially estimated range of $24-$27. The shares are to be listed on the Nasdaq under the ticker symbol "PPD."

Related Link: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

0

See more from Benzinga

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Visit link:
The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs - Yahoo Finance

Read More...

UVA Honors Its Leading Researchers at Boar’s Head Banquet – University of Virginia

Monday, February 3rd, 2020

The University of Virginias top leaders gathered Wednesday evening at the Boars Head Resort to honor faculty members from across Grounds for their outstanding contributions to their fields of study and societal impact through their research and scholarly activities.

University of Virginia President Jim Ryan presented the 2019 Research Achievement Awards to 13 UVA faculty members at the dinner event.

This is the first year of the Research Achievement Awards, Vice President for Research Melur Ram Ramasubramanian said. We believe that as a university, we are what we celebrate. We want to acknowledge the talented UVA faculty who are leaders in their fields and are impacting the world in positive ways.

Provost Elizabeth Liz Magill said, Were delighted to have a chance to celebrate the accomplishments and achievements of our faculty. From education policy to precision medicine to police-community relations, there are many different fields and individuals being honored by these awards.

Im awed and immensely grateful for the contributions the award winners have made to their respective fields and to the University of Virginia, Ryan said. Our strategic plan focuses a good deal of attention on supporting research. ... Our ultimate goal is to make it possible for researchers at UVA to do their very best work.

The awards covered excellence in research, collaboration, mentorship, public impact and innovation.

Pompano arrived at UVA in 2014 and assembled a robust research team in her lab. Pursuing new technologies and new questions, she is developing new approaches to study immunity. In the areas of immunoanalysis and immunoenineering, she is working to map out cellular activity in live tissues. Her group was recently awarded a large grant from the National Institutes of Health to develop an artificial lymph node on a microfluidic chip.

Dr. Pompano chose the road less travelled by pursuing entirely new technologies and questions, rather than the safer route of building on the experiences from her Ph.D. or postdoc work, Jill Venton, chair of the Department of Chemistry, said. This strategy required spending the first 2.5 years of her professorship laying new groundwork. Dr. Pompano is a research leader in the fields of analytical chemistry and immunoengineering.

Bassoks work is in early childhood education, and her focus has been to find a way for it to both meet high standards and make a difference in the lives of young children. To do this, she has partnered with policymakers and school districts in Virginia and Louisiana to study how early childhood education opportunities can happen at scale.

In the past four years, her work has accelerated. She has published 16 articles and received more than $6 million in grant funding. In 2017, Bassok was honored with the Presidential Early Career Award for Scientists and Engineers.

Daphna Bassok has raised the bar for the field and will motivate other scholars to do more insightful and rigorous work, said Katherine Magnuson, director of the University of Wisconsins Institute for Research on Poverty.

Alhusens research focuses on improving maternal and early infant health outcomes for disabled women and women living in poverty. Her research has been funded by the National Institutes of Health, the Health Resources and Services Administration and numerous foundations, and the goal of her work is to provide higher quality care to vulnerable populations.

She has received numerous awards for her work, including the Southern Nursing Research Society Early Science Investigator Award; the Association of Womens Health, Obstetric, and Neonatal Nurses Award for Excellence in Research; and School of Nursings Faculty Research Mentor Award.

Walsh is Lockhart B. McGuire Professor of Internal Medicine and directs the School of Medicines Hematovascular Biology Center. His research is focused on clonal hematopoiesis of indeterminate potential, or CHIP.

In his lab, he is looking at how mutations in blood cells lead to chronic diseases like heart attack and stroke. Through precision medicine, he is identifying and combatting the out-of-control multiplying process in these mutations to fight age-related diseases, as well as blood cancers like leukemia.

Walsh has published more than 350 scientific articles and he is the recipient of multiple research grants from the National Institutes of Health, including a MERIT Award. In 2011, the American Heart Association designated him a Distinguished Scientist by for his contributions to cardiovascular research.

Throughout his career, Scullys research, scholarship and teaching have focused on the science of how corrosion occurs and the engineering required to prevent it. He has conducted research and collaborated with scientists around the world in numerous industries such as energy, transportation, infrastructure, aerospace, maritime and microelectronics.

His projects include two U.S. Department of Energy Energy Frontier Research centers, two Department of Defense multi-university research initiatives, as well as grants from the National Science Foundation, PPG Industries and Axalta (formerly DuPont), and the U.S. Office of the Undersecretary of Defense.

Scully, the Charles Henderson Chaired Professor and chair of the Department of Materials Science and Engineering, also co-directs the Center for Electrochemical Science and Engineering, one of the leading centers in the world focusing on materials degradation. The center has generated more than $30 million in research funding in the last 10 years and graduates on average four to five Ph.D. students per year.

Scully is technical editor in chief of CORROSION, The Journal of Science and Engineering, the premier international research journal for the field. He serves in several capacities as an ambassador for the materials-corrosion field, including several meetings to debrief the U.S. Congress on materials degradation issues of national importance.

John Scullys contributions to corrosion can be characterized by quality, quantity and longevity, said Gerald S. Frankel, Ohio State University distinguished professor in materials science and engineering and a member of CORROSIONs editorial board. It is clear that he is a world leader, if not the world leader, in metal passivity, passivity breakdown and localized corrosion, and stress corrosion cracking.

In more his more than 20 years at UVA, Lambert has advanced the science of risk analysis and systems engineering. He has led more than 60 projects related to advanced logistics systems for a total of approximately $25 million in research funding.

Lambert, a professor in the Department of Engineering Systems and Environment, has focused on the disruption of system priorities by emergent and future conditions, including technologies, regulations, markets, environments, behaviors and missions. His work has been applied to disaster resilience, energy infrastructure, coastal protection, economic development, transportation, biofuels and Olympics planning, among other challenges.

His research has been cited more than 5,000 times across more than 200 publications. In 2019, he chaired the Fifth World Congress on Risk, convening more than 300 scientists in Cape Town, South Africa.

Professor Lambert is among the most accomplished and respected scientists of systems engineering and risk analysis in the world today, said Igor Linkov, Risk and Decision Science Team Lead for the U.S. Army Engineer Research and Development Center. Lambert in his research invented the application of scenario-based preferences in risk analysis.

Connelly, Morris and Grossman worked together on a multi-disciplinary project to examine how early life experiences affect the brain and social behaviors. The team studies the brain, as well as social and cognitive development, during the first two years of life, focusing on oxytocin and its role in social behavior. Their research has helped to illuminate gaps in our knowledge about behavioral development in humans, and helps us better understand healthy and atypical development.

They received a National Science Foundation Research Award in 2017 for their cutting-edge approach in combining epigenetic, neuroscience and behavioral methods across their three labs, and their work has led to several publications.

Moore is a busy physician-scientist with his own lab, and has recently become the division chief of Pediatric Gastroenterology, Hepatology, & Nutrition at UVA. He also co-wrote the application for a Trans-University Microbiome Initiative grant, which was funded last year by the Universitys Strategic Investment Fund in an effort to make UVA a center for microbiome research. But that has not stopped him from repeatedly aiding his colleagues and providing them with key resources when they needed them.

Three colleagues joined forces to nominate Moore for the mentorship award, mentioning his critical support, his generous sponsorship and advice, and his guidance as they dealt with grant applications and the logistics of their first accepted grants. Moore went above and beyond, donating lab space and reaching out to his networks to help them make the connections and give them a leg up in their careers.

Williams only arrived at Batten two years ago, but after the violent Unite the Right rally in Charlottesville in August 2017 he was able to immediately show the value of his research and public service engagement to the University community.

Starting before he came to the University, he has spent two decades doing research in the field on police-community relations around racial profiling, community policing and the need for law enforcement officers to work with their community on issues of public safety. In all his work, he strives to make an impact on communities by building relationships and tackling problems wherever they crop up.

Dr. Williams consistently uses his knowledge, experience and passion for the good of our city, Mindy Goodall, executive director of the Charlottesville Police Foundation, said. Charlottesville is fortunate to have gained him as a citizen and champion of police and community reconciliation.

The award for Innovator of the Year was presented to Dillingham and Ingersoll for their creation of PositiveLinks, an application designed to improve health outcomes and care for people living with HIV. They will give deliver a keynote lecture Feb. 18 in the Rotunda Dome Room.

Other researchers (in alphabetical order by school) were honored for being the top 25 in sponsored funding, top cited, national award winners, named to a national academy, or named as an outstanding researcher for their school:

Timothy Beatley, PlanningBarbara Brown Wilson, PlanningMona El Khafif, Urban & Environmental Planning

Jessica Connelly, PsychologyRita F. Dove, EnglishKevin Everson, ArtTobias Grossman, PsychologyL. Ilse Cleeves, AstronomyNitya Kallivayalil, AstronomyLee M. Lockwood, EconomicsJames P. Morris, PsychologyKen Ono, MathematicsRebecca R. Pompano, ChemistryMarilyne Stains, ChemistryAlan S. Taylor, History

Christopher Barrett, Director

David G. Mick, Marketing

Derrick P. Alridge, Leadership, Foundations and PolicyDaphna Bassok, Leadership, Foundations and PolicyRobert Q. Berry, Instruction and Special EducationCatherine Bradshaw, Human ServicesBenjamin L. Castleman, Leadership, Foundations and PolicyNancy L. Deutsch, Youth-NexJason Downer, Human ServicesSara E. Rimm-Kaufman, Leadership, Foundations and PolicyWilliam J. Therrien, Instruction and Special EducationArt Weltman, KinesiologyJoanna Lee Williams, Leadership, Foundations and PolicyAmada P. Williford, Human Services

Thomas H. Barker, Biomedical EngineeringHilary Bart-Smith, Mechanical and Aerospace EngineeringCraig H. Benson, Environmental EngineeringSteven M. Bowers, Electrical and Computer EngineeringJames T. Burns, Materials ScienceBenton H. Calhoun, Electrical and Computer EngineeringJoe C. Campbell, Electrical and Computer EngineeringGeorge J. Christ, Biomedical EngineeringJason L. Forman, Center for Applied BiomechanicsJeffery W. Holmes, Biomedical EngineeringPatrick E. Hopkins, Mechanical and Aerospace EngineeringKevin A. Janes, Biomedical EngineeringJames H. Lambert, Systems and EnvironmentXiaodong (Chris) Li, Mechanical and Aerospace EngineeringPamela M. Norris, Mechanical and Aerospace EngineeringElizabeth J. Opila, Materials ScienceMatthew B. Panzer, Mechanical and Aerospace EngineeringJohn R. Scully, Materials ScienceKevin Skadron, Computer ScienceMary Lou Soffa, Computer ScienceJohn A. Stankovic, Computer ScienceMalathi Veeraraghavan, Electrical and Computer Engineering

Brian N. Williams, Public PolicyJay Shimshack, Research Dean

Jayakrishna Ambati, OphthalmologyRuth Bernheim, Public Health SciencesAlison K. Criss, Microbiology /GIDIRebecca Dillingham, Infectious DiseasesLinda R. Duska, Obstetrics/Gynecology OncologyAnindya Dutta, Biochemistry/Molecular GeneticsW. Jeff Elias, NeurosurgeryEdward H. Egelman, Biochemistry/Molecular GeneticsRobin A. Felder, Clinical PathologyEric R. Houpt, Infectious DiseasesKaren Ingersoll, Psychiatry and Neurobehavioral SciencesKaren C. Johnston, NeurologyJaideep Kapur, NeurologyAnne K. Kenworthy, Molecular Physics and BiophysicsJonathan Kipnis, NeuroscienceRobert C. Klesges, Public Health SciencesBoris P. Kovatchev, Psychiatry and Neurobehavioral SciencesThomas P. Loughran, Oncology and MedicineColeen A. McNamara, Internal and Cardiovascular MedicineWladek Minor, Molecular Physics and BiophysicsSean R. Moore, PediatricsJames P. Nataro, PediatricsImre Noth, Internal and Pulmonary MedicineMark D. Okusa, NephrologyGary K. Owens, Cardiovascular Research, Molecular Physiology and Biological PhysicsKevin A. Pelphrey, NeurologyWilliam A. Petri, Internal Medicine and Infectious DiseasesKodi S. Ravichandran, MicrobiologyPatricio E. Ray, PediatricsStephen S. Rich, Public Health SciencesLukas K. Tamm, Molecular Physics and BiophysicsGregory C. Townsend, Internal Medicine and Infectious DiseasesKenneth Walsh, Internal and Cardiovascular MedicineKatharine Hsu Wibberly, Public Health SciencesMichael C. Wiener, Molecular Physics and BiophysicsMark Yeager, Molecular Physics and BiophysicsJames C. Zimring, Pathology

Jeanne L. Alhusen, Nursing

View post:
UVA Honors Its Leading Researchers at Boar's Head Banquet - University of Virginia

Read More...

Podcast: Why do I have to get a flu shot every year? – Chemical & Engineering News

Monday, February 3rd, 2020

Credit: Shutterstock

The flu virus, shown here as an illustration, evolves quickly, helping it escape our vaccines and immune systems.

Credit: Bethany Halford/C&EN

Although the Wuhan coronavirus is dominating headlines across the globe, influenza kills hundreds of thousands of people worldwide each year. In the US, millions of people roll up their sleeves annually for a flu shot. But this ritual is confusing for many. Why is it that most vaccines are effective for a lifetime while the flu vaccine is only effective for a year? And why do we sometimes get the flu even when weve gotten the vaccine? The answer is evolution: the flu is constantly evolving to evade our immune systems. In this episode of Stereo Chemistry, scientists who study flu evolution and pandemics explain what makes fighting the flu so difficult.

Subscribe to Stereo Chemistry now on Apple Podcasts, Google Podcasts, or Spotify.

The following is the script for the podcast. We have edited the interviews within for length and clarity.

StefanieOlsen: This is the info sheet from the CDC on the flu vaccine. Kind of who should get it, why you should get it, who shouldnt get it, what to expect, whats normal, whats not normal. All that sort of stuff. So Ill give you that for your perusal.

Matt Davenport: Thats Stephanie Olsen. Shes a nurse practitioner at a MinuteClinic in Cambridge, Massachusetts. Thats where C&EN senior correspondent Bethany Halford and her son went to get the flu vaccine back in the fall.

Stefanie Olsen: Are you a righty or a lefty?

Bethanys son: Im a righty.

Stefanie Olsen: OK. Cool. Well use your left arm. Find this big muscle. Here we go: clean, clean, clean. OK. One, two, three. Good job. Done. There you are.

Bethanys son: One tiny sting.

Stephanie Olsen: One tiny sting and done. Good job.

Matt: That didnt seem so bad.

Bethany Halford: It really wasnt bad at all.

Matt: Well hello there, Bethany.

Matt: Thanks so much for bringing your recorder along with you for the flu shot.

Bethany: No problem. Im actually glad I made this recording because I plan to replay it for my son every year just before we go to get our shots. Its a process thats met with no small amount of dread. But the Centers for Disease Control and Prevention recommend that most people get the flu vaccine every year.

Matt: So you and your son went in September. Its now almost February. Lets pretend youre a podcast cohost who has not gotten their flu shot. Is it too late?

Bethany: Well, CDC does recommend getting the flu vaccine by the end of October because it takes a few weeks for your body to create the antibodies that fight the virus. And this year the flu seems to be ramping up early. But doctors say that even now, its not too late to get the vaccine.

And were right in the thick of flu season. During the last flu season in the Northern Hemisphere, from October 2018 to May 2019, as many as 42.9 million people in the US got sick with the flu; 647,000 of those people were hospitalized, and 61,200 died.

Matt: Those numbers are from CDC, and theyre pretty typical for a flu season. So influenza is this huge problem, and its been that way for a long time. And its not going away, right? Unlike other vaccines, the flu shot is something you should get every year. And sometimes that flu shot isnt going to work.

Bethany: And this episode is all about how the flu outfoxes our vaccines and immune systems: through evolution. The flu virus is constantly changing itself to evade our immune systems response. And the virus changes enough each yearsometimes even enough within a single flu seasonthat the vaccine weve created is simply no longer effective.

Matt: So Beth, at the risk of sounding like a chemist right after the Nobel Prize announcement, isnt that a little more biology than chemistry?

Beth: Well, yes. But the evolutionary changes to influenza are really chemical changes. Theyre mutations in the viruss RNA that lead to amino acid changes in the viruss proteins. So there is plenty of chemistry to dig into. Were going to talk to three experts to learn how those changes happen and how studying them could help protect us better in the future. Well also look at what happens at the molecular level when a certain strain of flu becomes a pandemic that spreads quickly across the globe.

And were going to start by talking to a chemist.

Jesse Bloom: Hi, my name is Jesse Bloom.

Bethany: Jesse studies protein evolution at the Fred Hutch Cancer Research Center in Seattle. Hes also affiliated with the University of Washington and the Howard Hughes Medical Institute.

Sign up for C&EN's must-read weekly newsletter

Jesse Bloom: I actually did my PhD in chemistry, working with Frances Arnold, who studied the directed evolution of proteins.

Matt: Wait. The Frances Arnold?

Bethany: Yes, the Frances Arnold from Caltech who won a share of the 2018 Nobel Prize in Chemistry.

Jesse Bloom: After working with Frances, I remained really interested in protein evolution, but I wanted to study the evolution of proteins in a context with biomedical significance. So my lab now focuses on viral evolution, particularly the evolution of influenza virus. And the reason for that is these viruses evolve their proteins very rapidly.

Bethany: Jesse says there are really two main forms of flu evolution. One is called antigenic drift, and the other is called antigenic shift.

Matt: I like the rhyme scheme.

Bethany: Catchy, right? So lets start with the drift.

Jesse Bloom: Antigenic drift is the much more common form of flu evolution, and that essentially can be thought of as last years strain or a couple years ago strain of human flu evolving to be a little bit different, each year. Our immune systems are actually great at mounting antibody responses that protect us against flu, and theres pretty good evidence that if youre infected with a particular strain of flu, your body will provide very good, long-lasting immunity to that particular strain of flu.

Bethany: So, if our bodies provide long-lasting immunity, Im sure youre wondering why we still have to get a flu shot every year.

Bethany: Heres how Jesse explains it.

Jesse Bloom: The challenge with flu is the virus evolves very rapidly. In particular, the positions on the viral proteins that are recognized by our immune system, primarily by our antibodies, change, and they change enough that after about 5 years, many of those antibodies sort of dont work anymore. So antigenic drift and what typically is responsible for the seasonal influenza outbreaks is the virus that was present last year or the year before changing a little bit so that after about 5 years, its mostly evaded your immune systems memory.

Bethany: Now, I told you this was a chemistry story, so before we go any further, let me give you a picture of what Jesse is talking about. There are two proteins that scientists think are most important with respect to immunitywe create antibodies that bind to these two proteins in order to mount a defense against influenza. The first protein is hemagglutinin, which helps the influenza virus latch on to cells and infect them. The second is neuraminidase, which helps cleave new virus particles away from infected cells so the virus can continue to attack healthy cells. If you think of the flu virus as a sort of blob, hemagglutinin and neuraminidase stick out of that blob like pins in a pin cushion. Scientists name different strains of flu based on which types of hemagglutinin and neuraminidase they have.

Matt: Are those the proteins were referring to when we talk about like H1N1 influenza or H3N2 influenza ?

Bethany: Thats right. Right now, there are three types of flu circulating in humans: H1N1, H3N2, and influenza B.

Jesse Bloom: I mean, they all evolve pretty fast, like, compared to almost anything else we encounter in life. But definitely H3N2 evolves the fastest. H1N1 is sort of in the middle. And influenza B is the slowest, although influenza B is still pretty fast. And this plays outfor instance, influenza B is most known for infecting children because its relatively less good at escaping immunity. Obviously children dont have any immunity at all, if they havent been vaccinated, anyway, to escape. So theyre always going to be susceptible. And then H3N2 is sort of best at infecting older peopleits also good at infecting younger people, but its good at affecting all agesand probably the reason is that H3N2 is evolving the fastest. So it can best get away from that prior immunity.

Matt: So, when he says something is evolving fast, what does that mean on a molecular level?

Bethany: Take H3N2 influenza, for example. The hemagglutinin protein on H3N2 will change three to four of its amino acids every yearan evolution rate that Jesse says is extraordinarily high.

Matt: OK, so I understand why these gradual changesthe antigenic driftmake it so that we have to get the flu vaccine every year. But why dont we need frequent vaccinations for all RNA viruses? Like measles?

Bethany: CDC recommends just two shots for measles as part of whats called the MMR vaccine. It protects you from measles, mumps, and rubella. You get the first shot when youre about a year old, the other when youre about 5 years old. It seems that the parts of the measles virus that the immune system goes afteror makes antibodies forjust dont seem to be changing that much. We know this because before the measles vaccine existed, people who got measles only got it once in their lifetime. And in the 50 or so years since weve had the vaccine, people who get it dont get measles. As Jesse explains, theres no reason measles cant drift like the flu, thats just not what we see. So the thinking is that measles is mutating, but not in a way that helps the virus. Its not as wily as influenza.

Matt: That is super interesting. But . . .

Bethany: How does knowing this help fight the flu?

Bethany (in interview): Can you talk a little bit about how studying flus evolution can help us fight the virus?

Jesse Bloom: So first, the way the flu vaccines are made currently, theres sort of this forecasting problem. We know that the vaccine works better when the vaccine is more similar to the virus that is infecting people. But it takes a while, maybe about 9 months, to really produce enough vaccine to be given to everybody. And because the virus is changing a little bit every year, you have to predict what virus is going to be circulating 9 months in the future. So you basically have to say, How do we think the virus is going to be evolving? And so by understanding the viruss evolution, we can make better decisions about which flu strain should go in the flu vaccine. And when those decisions are better, the vaccine will work better.

Bethany (in studio): Jesse also says that studying evolution helps scientists understand which parts of the flu virus change the least or mutate less frequently. It could be that some of these less-dynamic parts of the flu could become targets for longer-lasting vaccines.

Matt: I can dig it. So whats driving the evolution? Whats making the proteins change?

Bethany: Good question. Lets get another influenza evolution expert to chime in.

Adam Lauring: So Im Adam Lauring. Im an associate professor here at the University of Michigan. I am a physician-scientist, which means I spend part of my time actually doing clinical work in infectious diseases. But most of my time I spend actually running a research lab, in which we study virus evolution, including influenza virus. Evolution is really for me kind of the be all, end all in the problem of influenza. Evolution has immediate and real-world impacts.

Bethany (in interview): When we say flu is evolving, what is actually going on?

Adam Lauring: At its simplest, the flu will mutate, and that means that its making changes in its genome which will lead to changes in its proteins, and those protein changes will make the virus different. And then theres selection. And so viruses that are better at doing what viruses do will take over, and the viruses that are less fit will die away. And so its kind of like you learned when you first learned biology: its survival of the fittest, or the best one wins. And so the virus is mutating all the time, and the ones who are best able to make copies of themselves and spread from person to person are going to become the new viruses and replace the old ones.

Bethany (in studio): Now, flu evolution is a complex process thats influenced by many things. But one thing that helps flu evolve especially fast is that its an RNA virus. That means its genes are stored in ribonucleic acid, or RNA. RNA viruses, in general, evolve faster than viruses that store their genetic information in DNA. Both DNA and RNA viruses have proteins called polymerases, and the job of these proteins is to make copies of the viruss genetic code. DNA polymerases, however, have a built-in proofreading function. They can check their work for mistakes and correct them. RNA polymerases dont do that.

Adam Lauring: Because of this, most RNA viruses have mutation rates or error rates that are about a thousandfold higher than for DNA viruses. That means that an RNA virus can generate mutants way more quickly, and then some of those mutants will confer an advantage to the virus, and that will lead to faster evolution.

Bethany: Adam says that all of the flu viruss proteins can and are evolving but that mutations to the hemagglutinin and neuraminidase proteinsthe Hs and Nsare the ones that matter most.

Adam Lauring: Mutations in those proteins tend to make a bigger difference in terms of whether the virus succeeds or fails, and a major reason is those proteins, theyre on the surface of the virus, and so theyre targeted by the immune system. And so you have antibodies targeting those proteins. So if a virus figures out a way to escape those antibodies, it will do better than its brothers and sisters.

Bethany: So weve been talking a lot about mutation, but Adam also points out that theres a lot more to evolving quickly than just how fast a virus mutates. For instance, the number of people infected could play a role. The example he gave me is the more people infected, the more opportunities the virus has to evolve. Thats because a greater diversity of people would mean a wider variety of immune systems, and the virus would need to generate new or different versions of itself to survive.

Adam Lauring: Broad strokes, flu does evolve quickly but maybe not for the reasons we typically think. And there are probably subtleties yet to be uncovered.

Bethany: To try to uncover some of those subtleties, Adams lab has been collaborating with Arnold Monto and Emily Martin, who are epidemiologists at the University of Michigan School of Public Health. For about 8 years, they have been following 300 or so Michigan families to see what viruses are circulating among them and how their immunity changes over time. The flu virus is part of this sampling. As part of the work, they collect nose and throat swabs anytime someone from one of those families gets sick.

Matt: Oh, wait. Everyone gets swabbed when anyone gets sick?

Bethany: Right. Heres why.

Adam Lauring: Its really kind of a slice of what flu is doing locally, and youre not really biased by only getting sick people or people who tend to go to the doctor.

Bethany: Adams group realized that the collection of samples the epidemiologists had accumulated gave them a great opportunity to see how flu viruses were evolving outside of a laboratory. So they raided the freezer and then did in-depth genetic sequencing of all the influenza viruses they found.

Adam Lauring: The virus makes a lot of mutations. Everybodys flu viruses, their population is actually a little bit different. So I could have the flu and you could have the flu and wed be in the same room, but our flu viruses might be a little bit different if you really looked hard enough. And so what were able to do with our sequencing is really understand those subtle differences in kind of the overall flu mixture that each person has in them.

Bethany: And then they compare, see which versions are actually being transmitted from person to person.

Adam Lauring: And that is really important in understanding evolution, right, because you may generate all sorts of cool viruses inside you. But if they dont make it onto the next person, its kind of a dead end. And that virus could be the most awesome virus there is, but if it doesnt get transmitted, its gone forever. And so what we tried to do is understand exactly how many viruses kind of go across from one person to the next. And we found that its actually a really small number. Its hard for a new virus to kind of make it both within a host and to get on to the next host.

Matt: Thats wild. So, if its hard for a new flu virus to survive within a host and also hard for that virus to make it to the next host, how is that much evolution happening? Why do we still need to get the flu vaccine every year?

Bethany: Adam says its really just a numbers game. Hundreds of millions of people are infected with the flu each year, which gives the virus lots of opportunities to make a successful mutant.

Adam Lauring: One analogy I give is flu viruses are sort of like people playing the slot machines. And so most of the time the virus is losing when you talk about kind of on an individual host or in a household. But if you have a hundred million people playing the slot machines, youre going to hit the jackpot with some frequency.

Matt: I like that analogy. Its kind of empowering. Like humanitys the house and the flus a rube giving us their money.

Bethany: Sure. Just remember, the flus currency isnt money. Its trying to survive, and when it thrives, it makes you sick. So its not like a casino catches fire whenever someone hits the jackpot. And the analogy really works best for antigenic drift. Weve got a whole other type of evolution to talk aboutremember how I said there were two? This second kind leads to pandemics, and well talk about it . . . after the break.

Matt: Hey. Sorry to leave you hanging like that, but dont worry. Theres going to be a silver lining. Were not just going to be like. The flu. Yeah, its brutal. Welp, see you later.

Thats the great thing about covering chemistry. Its that were not just talking about problems, were talking to the people solving them.

In fact, earlier this month, Leigh Krietsch Boerner wrote a phenomenal piece for C&EN about how researchers are examining the effectiveness of flu shots, especially vaccines made using eggs.

Weve got a link to Leighs story in the description, but if you want to inoculate yourself against the possibility of missing more of our great coverage, sign up for our newsletter. Well send a weekly dose of chemistrys biggest goings-on right to your inbox. Head to cenm.ag/newsletter to subscribe.

Matt: So, Bethany, you said there were two main forms of influenza evolution: antigenic drift, which weve been talking about. But there was also, what was that rhyme again?

Bethany: Antigenic shift.

Matt: Right, antigenic shift. Whats that?

Bethany: When the influenza virus undergoes antigenic shift, it experiences a much larger change. It changes so much, in fact, that we usually dont have much of an antibody arsenal built up to fight it.

Matt: And how does it make such a dramatic shift?

Bethany: So, antigenic shift can happen a few different ways. Another way flu is different from measles is that flu doesnt just circulate in people. It also circulates in many other animal species, like pigs and whales and birds.

Bethany: Yeah. But it turns out, the vast majority of influenza strains that exist in the world actually are circulating in wild waterfowl. And sometimes those viruses will jump from birds to people or from birds to pigs to people, for example.

A single animal can also get infected by two different strains of flu from two other animals. Those viruses then swap some of their genetic material to make a new, third strain.

However its happening, when the flu is evolving outside of humans, vaccine makers and our immune systems are largely blind to what these viruses look like. That means if one of these viruses does jump to humans, it could hit us hard. Were talking global pandemic here. Thats because the virus would look very different from anything our immune systems have seen, and we might have little or no ability to recognize the strain or fight it.

Matt: That sounds gnarly. And a little scary.

Bethany: It is. Global flu pandemics occur when a novel influenza virus spreads quickly around the globe.

Matt: Is that why were so concerned when people get infected with flu on chicken farms, for example?

Bethany: Yes. And you may have heard about the recent outbreak that started in Wuhan, China. Thats a coronavirusso, not the flubut its another example of a pathogen that made the jump into people from animals. But theres actually a lot more to becoming a global pandemic than just generating a virus people havent seen before. Lets talk to someone who studies how global influenza pandemics emerge.

Seema Lakdawala: My name is Seema Lakdawala. I am an assistant professor at the University of Pittsburgh in the School of Medicine and the Department of Microbiology and Molecular Genetics.

Bethany: Seema says there are several hurdles a new virus has to overcome before it can become a pandemic

Seema Lakdawala: And the first hurdle is that they have to be able to infect the human host. And so its hard for some viruses that may be emerging in birds to infect the human hosts unless theres access. And so it doesnt happen as readily, but that does happen in many occasions.

Matt: That makes sense, right? Its kind of like what Adam was talking about earlier. How you can have all these cool bugs being made in humans, but if they cant survive, and if they cant make the leap in humans, they really arent a threat.

Bethany: Right. And Seema says the next hurdle, after a virus has made it into a human, is the virus being able to survive in respiratory systems. In humans, the flu is a respiratory infection, but in birds, its gastrointestinal. Influenza virus can move from birds to people through contact with feces or other secretions, butdont worrynot from eating poultry or eggs.

Read more from the original source:
Podcast: Why do I have to get a flu shot every year? - Chemical & Engineering News

Read More...

Colombia’s first ever science minister faces calls to resign over fungi-based cancer treatment – Science Magazine

Monday, February 3rd, 2020

Mabel Gisela Torres Torres, Colombias new minister of science, is under fire for giving cancer patients a fungi extract.

By Rodrigo Prez Ortega Feb. 3, 2020 , 4:33 PM

In December 2019, when Colombian President Ivn Duque Mrquez appointed molecular biologist Mabel Gisela Torres Torres to be the first head of the newly created Ministry of Science, Technology and Innovation, only a few of the nations researchers knew who she was.

Torres was a total stranger, recalls Gustavo Quintero Hernndez, dean of the School of Medicine and Health Sciences at Del Rosario University.

Now, Torres is obscure no moreand finds herself at the center of controversy that has included calls for her resignation.

The storm began on 10 January, 1 day before Torres took office, when the newspaper El Espectador published a story raising questions about her research record. The story reported a claim Torres made, during a broadcast interview in August 2019, that she had essentially run an informal, uncontrolled clinical trial with cancer patients. Torres said she had given a brew made from a fungus she was studying to patients with cervical, breast, and brain cancer, and that their health had improved. She didnt seek formal ethical, safety, and efficacy reviews prior to starting the work because it would have taken too long, and because she believed the fungus posed no threat to human health, she told the same paper the next day. She also said she hasnt published the extensive data she has claimed to collect from such studies as an act of rebellion, although she plans to submit an application to patent her findings.

Torress remarks drew immediate condemnation from many Colombian scientists, with more than six scientific and medical societies issuing statements of concern. We cannot accept derogatory attitudes in relation to the scientific method, the laxity with ethical codes of scientific experimentation, and of disdain for the process of publication and peer review, said the Colombian Academy of Exact, Physical and Natural Sciences in a statement.

We can only regret that the course of how to do science in our country has been left in the hands of pseudoscience, said the Colombian Association of Medical Faculties (ASCOFAME) in a statement.

Some researchers believe Torres should step down. We want her to resign, says Juan Manuel Anaya, an immunologist at Del Rosario University. Her act of offering a hope for patients with cancer has to be criticized, he says, because it was unethical and eventually dangerous.

Torres did not respond to requests for comment from ScienceInsider. But on 30 January she told the newspaper El Tiempo that she would not resign. I have always believed that [being appointed minister] is no accident, she said.

In an earlier statement, Torres defended her work, which focused on the taxonomy, genetics, and bioactive compounds of fungi in the genus Ganoderma. At no time have I stated in a simplistic way that this species is the cure against cancer, she wrote in the 18 January statement. I have not offered a medicine, let alone commercialized it. I have rigorously observed the ethics protocols established for scientific experimentation in general and those that apply specifically in my disciplinary field.

The controversy had disheartened many researchers who just 1 year ago were celebrating a successful push to create Colombias first science ministry. It has been very frustrating. We hoped that we get started on the right foot, says Lucy Gabriela Delgado Murcia, an immunologistat the National University of Colombia, Bogot. She was part of the Misin Internacional de Sabios, an advisory group of 47 members of the national and international scientific community that helped set goals for the new ministry.

Its very astonishing that a person who has difficulty [adhering to] the scientific method is the person that will lead the science of this country, says physician Quintero Hernndez, president of the board of ASCOFAME.

Others are withholding judgment. Laura Guzmn Dvalos, who was Torress Ph.D. adviser at the University of Guadalajara, described Torres as a brilliant student and notes that studies have suggested metabolites in the fungi Torres studied have shown potential as a cancer treatment in cell and mouse studies. And she says that although she is not aware of any clinical studies in humans, I dont think its a bad idea that Torres gave her fungi brew to patients. The fungi is meant to complement, not replace, traditional cancer treatments such as chemotherapy, she notes. She herself takes a supplement derived from fungi, Dvalos says, and many professors at her university give the supplements to cancer patients.

Marine biologist Juan Armando Snchez Muoz of the University of Los Andes, who was also a member of the Misin Internacional de Sabios, says he wishes Torres would be more emphatic on her comments on the scientific method and medical ethics. But he also notes that, in her current position, her job isnt to do science but to administrate research programs and funding. We have to give her chance to demonstrate that she can do it, he says.

Excerpt from:
Colombia's first ever science minister faces calls to resign over fungi-based cancer treatment - Science Magazine

Read More...

Academia Gets The First Production Cray Shasta Supercomputer – The Next Platform

Monday, February 3rd, 2020

Indiana University is the proud owner of the first operational Cray Shasta supercomputer on the planet. The $9.6 million system, known as Big Red 200 to commemorate the universitys 200th anniversary and its school colors, was designed to support both conventional HPC as well as AI workloads. The machine will also distinguish itself in another important way, being one of the worlds first supercomputers to employ Nvidias next-generation GPUs.

We will get to that in a moment.

Although Big Red 200 is the first Shasta system to be up and running, it is one in a pretty long line of machines that Cray, now a unit of Hewlett Packard Enterprise, hopes to deploy in the coming decade based on this architecture. Notably, Shasta was tapped by the Department of Energy to be the basis of its first three exascale systems. Later this year, Berkeley Lab will be the recipient of a pre-exascale Shasta system, in this case, the NERSC-9 machine, code-named Perlmutter. Big Red 200 will have just a fraction of the capacity of those super-sized systems, but the use of Nvidias upcoming GPUs will make it a unique resource for anyone with access to the machine.

Those GPUs are expected to be plugged into Big Red 200 later this summer that according to Brad Wheeler, vice president for information technology and chief information officer. The exact nature of those GPUs is unknown, which is understandable, inasmuch as Nvidia has not announced they are even on the way. The most likely explanation is that they will be the next-generation Tesla GPUs based on the upcoming Ampere architecture.

Our best guess is that Ampere GPUs will be unveiled in March at Nvidias GPU Technology Conference, which suggests they will be ready to ship in time for their summer rendezvous at IU. Note the Berkeley Labs Perlmutter system is also in line for these next-generation Nvidia chips in the same general timeframe as the Big Red 200 upgrade.

According to Wheeler, the addition of the new GPUs was something of a fluke. The original plan was to outfit the system with Nvidia V100 GPUs, which would have brought its peak performance to around 5.9 petaflops. But as they were getting ready to receive the system, an opportunity presented itself to wait a bit longer and move up to Nvidias newer technology. At the last minute, we decided to take the machine in two phases, explained Wheeler.

The first phase of the system the one currently up and running at IU is comprised of 672 dual-socket nodes powered exclusively by CPUs, in this case, Rome Epyc 7742 processors from AMD. (Yes, AMD ate Intels lunch yet again in another high-profile HPC deal). The second phase of the new IU supercomputer will commence this summer and will bring additional AMD Rome nodes online and these will be equipped with one or more of the next-generation Nvidia GPUs. When all is said and done, Big Red 200 is expected to deliver close to 8 petaflops.

As a result of the two-phase approach, waiting a few more months yielded an additional two petaflops of performance, even though, according to Wheeler, they ended up buying a smaller number of GPUs. (The newer silicon is expected to deliver 70 percent to 75 percent more performance than that of the current generation.) Perhaps more importantly, having the latest and greatest GPUs will help attract additional research dollars to the university, especially for AI-enabled research.

Speaking of which: The university is particularly interested in pointing out the artificial intelligence capabilities of the new machine, claiming that it will be the fastest university-owned AI supercomputer. Of course, until the new GPUs are unveiled, we wont really know the extent of those capabilities, but they are almost sure to be more impressive than that of the current V100, which is certainly no slouch in that regard. Although, Big Red 200 is expected to deliver about eight times the peak performance of its predecessor, Big Red 2, Wheeler told us that for AI work, it will be a far bigger jump.

That is because Big Red 2, which was installed in 2013, was equipped with the now-ancient Kepler Tesla K20 GPU accelerators. That processor topped out at 1.18 FP64 teraflops and 3.52 FP32 teraflops. It had no specialized logic for machine learning, such as the Tensor Cores employed in the current Volta GPUs, or even FP16 capability, as is coming to many different compute engines in both the raw and bfloat16 flavor invented by Google and increasingly in favor. Big Red 2 was dismantled in December 2019 to make room for its successor, after having served IU researchers for seven years.

The new GPUs are certain to get a workout at IU. Researchers there are already applying AI techniques in areas like medical research and molecular genetics, cybersecurity, fraud prevention, and neuroscience, to name a few. Of course, the new system will also be expected to support more conventional HPC workloads, including the usual suspects such as climate modeling, genomic analysis, and particle physics simulations. Depending on the code employed, the GPUs could come in handy in these domains as well. There were so many things being done algorithmically to really start to enable GPU use across a range of research disciplines and methods, notes Wheeler.

To make up for the slight delay in GPU deployment, the university is upgrading its Carbonate cluster with 96 additional Tesla V100 accelerators. It was previously outfitted with 16 P100 GPUs and 8 V100 GPUs according to the systems webpage, and was the main resource for IU researchers that needed modern AI hardware. The additional V100s will provide some extra capacity until phase two of Big Red 200 comes online.

Featuring highlights, analysis, and stories from the week directly from us to your inbox with nothing in between.

Subscribe now

See more here:
Academia Gets The First Production Cray Shasta Supercomputer - The Next Platform

Read More...

Study likens Earth’s evolution to creation of Frankenstein’s monster – Harvard Gazette

Monday, February 3rd, 2020

Modern biology relies on relatively homogeneous building blocks to encode genetic information, said Seohyun Kim, a postdoctoral researcher in chemistry and first author on the paper. If Szostak and Kim are right and Frankenstein molecules came first, why did they evolve to homogeneous RNA?

Kim put them to the test, pitting potential primordial hybrids against modern RNA and manually copying the chimeras to imitate the process of RNA replication. Pure RNA, he found, is more efficient, more precise, and faster than its heterogeneous counterparts. In another surprising discovery, Kimfound that the chimeric oligonucleotides like ANA and DNA could have helped RNA evolve the ability to copy itself. Intriguingly, he said, some of these variant ribonucleotides have been shown to be compatible with or even beneficial for the copying of RNA templates.

If the more efficient early version of RNA reproduced faster than its hybrid counterparts, it would, over time, out-populate its competitors. Thats what the Szostak team theorizes happened in the primordial soup: Hybrids grew into modern RNA and DNA, which then outpaced their ancestors and, eventually, took over.

No primordial pool of pure building blocks was needed, Szostak said. The intrinsic chemistry of RNA copying would result, over time, in the synthesis of increasingly homogeneous bits of RNA. The reason for this, as Seohyun has so clearly shown, is that when different kinds of nucleotides compete for the copying of a template strand, it is the RNA nucleotides that always win, and it is RNA that gets synthesized, not any of the related kinds of nucleic acids.

So far, the team has tested only a fraction of the possible variant nucleotides available on early Earth. So, like those first bits of messy RNA, their work has just begun.

Read the rest here:
Study likens Earth's evolution to creation of Frankenstein's monster - Harvard Gazette

Read More...

Study finds THC rises in hemp due to genetics, not growing conditions – New Food

Monday, February 3rd, 2020

Researchers from Cornell University studied hemp from two sites to determine whether the difference in growing conditions affected THC levels.

As the hemp industry grows, producers face the risk of cultivating a crop that can become unusable and illegal if it develops too much of the psychoactive chemical THC, according to researchers from Cornell University. The researchers have determined that a hemp plants propensity to go hot become too high in THC is determined by genetics, not as a stress response to growing conditions, which is said to be contrary to popular belief.

[People thought] there was something about how the farmer grew the plant something about the soil, the weather getting too hot, or drought, said Larry Smart, Horticulture Professor and senior author of the study, but our evidence from this paper is that fields go hot because of genetics, not because of environmental conditions.

Smart and his team conducted field trials at two sites, studying the genetics and chemistry of 217 hemp plants. They found that differences in growing conditions between the sites had no significant influence on which chemicals the plants produced. But when they compared the CBD (cannabidiol) and THC levels of each of the plants against their genomes, they found very high correlation between their genetics and the chemicals they produced.

Jacob Toth, first author of the paper and a doctoral student in Smarts lab, developed a molecular diagnostic to demonstrate that the hemp plants in the study fell into one of three genetic categories: plants with two THC-producing genes; plants with two CBD-producing genes; or plants with one gene each for CBD and THC.

To minimise the risk of plants going hot, hemp growers ideally want plants with two CBD-producing genes, the researchers explained.

While conducting the research, the team also discovered that as many as two-thirds of the seeds they obtained of one hemp variety which were all supposed to be low-THC hemp produced THC above legal limits.

The researchers explained that they hope their work will help address this problem by providing breeders with easy-to-use genetic markers that can be utilised much earlier on seedlings and both sexes of plants.

View original post here:
Study finds THC rises in hemp due to genetics, not growing conditions - New Food

Read More...

Human Genetics Market 2020 Projections, SWOT Analysis, Size and Forecast by 2026 | QIAGEN, Agilent Technologies, Thermo Fisher Scientific – Jewish…

Monday, February 3rd, 2020

Global Human Genetics market 2020 in depth research by industry competitive landscape, size, growth rate, strategy, trends and forecast 2026.

The report on the global Human Genetics market is just the resource that players need to strengthen their overall growth and establish a strong position in their business. It is a compilation of detailed, accurate research studies that provide in-depth analysis on critical subjects of the global Human Genetics market such as consumption, revenue, sales, production, trends, opportunities, geographic expansion, competition, segmentation, growth drivers, and challenges.

Get the Sample of this [emailprotected]https://www.qyresearch.com/sample-form/form/1494807/global-human-genetics-market

As part of geographic analysis of the global Human Genetics market, the report digs deep into the growth of key regions and countries, including but not limited to North America, the US, Europe, the UK, Germany, France, Asia Pacific, China, and the MEA. All of the geographies are comprehensively studied on the basis of share, consumption, production, future growth potential, CAGR, and many other parameters.

Market Segments Covered:

The key players covered in this studyQIAGENAgilent TechnologiesThermo Fisher ScientificIlluminaPromegaLabCorpGE

Market segment by Type, the product can be split intoCytogeneticsPrenatal GeneticsMolecular GeneticsSymptom Genetics

Market segment by Application, split intoResearch CenterHospitalForensic Laboratories

Regions Covered in the Global Human Genetics Market:

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report Accurate market size and CAGR forecasts for the period 2019-2025 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Human Genetics market Exhaustive research on innovation and other trends of the global Human Genetics market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report offers a complete company profiling of leading players competing in the global Human Genetics market with high focus on share, gross margin, net profit, sales, product portfolio, new applications, recent developments, and several other factors. It also throws light on the vendor landscape to help players become aware of future competitive changes in the global Human Genetics market.

Get Customized Report in your Inbox within 24 hours @https://www.qyresearch.com/customize-request/form/1494807/global-human-genetics-market

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Human Genetics market

Chapter 2: Evaluating the leading manufacturers of the global Human Genetics market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Human Genetics market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9 : To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

About Us:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original:
Human Genetics Market 2020 Projections, SWOT Analysis, Size and Forecast by 2026 | QIAGEN, Agilent Technologies, Thermo Fisher Scientific - Jewish...

Read More...

Don’t believe the conspiracy theories you hear about coronavirus and HIV – Massive Science

Monday, February 3rd, 2020

The 2019 novel coronavirus (2019-nCoV) outbreak has sparked a speedy response, with scientists, physicians, and front-line healthcare professionals analyzing data in real-time in order to share findings and call out misinformation. Today, The Lancet published two new peer-reviewed studies: one which found that the new coronavirus is genetically distinct from human SARS and MERS, related viruses which caused their own outbreaks, and a second which reports clinical observations of 99 individuals with 2019-nCoV.

The first cases of the coronavirus outbreak were reported in late December 2019. In this new study, Nanshan Chen and colleagues analyzed available clinical, demographic, and laboratory data for 99 confirmed coronavirus cases at the Wuhan Jinyintan Hospital between Jan 1 to Jan 20, 2020, with clinical outcomes followed until 25th January.

Chen and colleagues reported that the average age of the 99 individuals with 2019-nCoV is around 55.5 years, where 51 have additional chronic conditions, including cardiovascular and cerebrovascular (blood flow to the brain) diseases. Clinical features of the 2019-nCoV include a fever, cough, shortness of breath, headaches, and a sore throat. 17 individuals went on to develop acute respiratory distress syndrome, resulting in death by multiple organ failure in 11 individuals. However, it is important to note here that most of the 2019-nCoV cases were treated with antivirals (75 individuals), antibiotics (70) and oxygen therapy (75), with promising prognoses, where 31 individuals were discharged as of 25th January.

Based on this sample, the study suggests that the 2019 coronavirus is more likely to affect older men already living with chronic conditions but as this study only includes 99 individuals with confirmed cases, it may not present a complete picture of the outbreak. As of right now, there are over 6,000 confirmed coronavirus cases reported, where a total of 126 individuals have recovered, and 133 have died.

In a second Lancet study, Roujian Lu and their fellow colleagues carried out DNA sequencing on samples, obtained from either a throat swab or bronchoalveolar lavage fluids, from eight individuals who had visited the Huanan seafood market in Wuhan, China, and one individual who stayed in a hotel near the market. Upon sequencing the coronaviruss genome, the researchers carried out phylogenetic analysis to narrow down the viruss likely evolutionary origin, and homology modelling to explore the virus receptor-binding properties.

Lu and their fellow colleagues found that the 2019-nCoV genome sequences obtained from the nine patients were very similar (>99.98% similarity). Upon comparing the genome to other coronaviruses (like SARS), the researchers found that the 2019-nCoV is more closely related (~87% similarity) to two bat-derived SARS-like coronaviruses, but does not have as high genetic similarity to known human-infecting coronaviruses, including the SARS-CoV (~79%) orMiddle Eastern Respiratory Syndrome (MERS) CoV (~50%).

The study also found that the 2019-nCoV has a similar receptor-binding structure like that of SARS-CoV, though there are small differences in certain areas. This suggests that like the SARS-CoV, the 2019-nCoV may use the same receptor (called ACE2) to enter cells, though confirmation is still needed.

Finally, phylogenetic analysis found that the 2019-nCoV belongs to the Betacoronavirus family the same category that bat-derived coronaviruses fall into suggesting that bats may indeed be the 2019-nCoV reservoir. However, the researchers note that most bat species are hibernating in late December, and that no bats were being sold at the Huanan seafood market, suggesting that while bats may be the initial host, there may have been a secondary animal species which transmitted the 2019-nCoV between bats and humans.

Its clear that we can expect new findings from the research community in the coming days as scientists attempt to narrow down the source of the 2019-nCoV.

See the original post:
Don't believe the conspiracy theories you hear about coronavirus and HIV - Massive Science

Read More...

Bent into shape: The rules of tree form – Knowable Magazine

Monday, February 3rd, 2020

Theres a place in West Virginia where trees grow upside-down. Branches sprout from their trunks in the ordinary fashion, but then they do an about-face, curving toward the soil. On a chilly December day, the confused trees bare branches bob and weave in the breeze like slender snakes straining to touch the ground.

Its really kind of mind-boggling, says plant molecular biologist Chris Dardick, waving toward the bizarro plum trees. Theyre completely messed up.

Im visiting an orchard at the Appalachian Fruit Research Station, an outpost of the US Department of Agriculture nestled in the sleepy Shenandoah Valley. Here, at Dardicks workplace, the disoriented plums are but one in an orchard of oddities, their outlines, seasonally stripped of leaves, standing out in stark relief.

There are trees with branches that shoot straight up, standing to attention in disciplined rows, with nary a sideways branch. There are trees with branches that elegantly arch, like woody umbrellas; others with appendages that lazily wander this way and that.

Dwarf trees crouch, sporting ball-like crowns akin to Truffula trees. Compact trees poke from the ground in clumps of scraggly, knee-high sticks. Apple trees with some hidden predicaments grow in a greenhouse nearby: Their roots reach sideways rather than down. The topsy-turvy growth of all of these trees comes from genetic variations that cause the dialing up, dialing down or elimination altogether of the activity of key genes controlling plant architecture.

Understanding these misfits has real-world applications: It could help grow the next generation of orchards that, densely packed with trees, produce more fruit while using less land and labor than today. But Dardick is also trying to answer a fundamental question: How do different trees get their distinctive shapes? From the towering spires of spruce and fir, the massive spreading limbs of an oak to the stately arching canopies of an elm, the skeletal shapes of trees offer signature silhouettes.

Dardicks work and that of other researchers also could help to explain how the shapes of individual trees are far from fixed. Trees, much more than we can, will morph in response to their literal neck of the woods. Limbs in the shade reach toward spots of sunlight. Trees on windswept hills bend trunk and branches into gnarled architectures.

The familiar shape of a regular plum tree (left) is transformed by dialing down the activity of certain plant architecture genes, leading to plums with erect branches that shoot straight up (middle) or plums with branches that cascade downward (right).

CREDIT: C. HOLLENDER (LEFT), C. DARDICK (CENTER AND RIGHT)

Work by breeders, biologists and botanists have revealed sizable pockets of knowledge about the hormones, genes and processes that yield the diverse shapes of trees and other plants, between species and within species. It has not been easy: Two of trees most appealing attributes their long lives and large sizes make them intractable research subjects.

But as scientists pursue these questions, commonalities are emerging between vastly different species. The puzzle of shape diversity and adaptability turns out to be tied to the fundamentals of being a plant: grappling with gravity, fighting for sunlight, all while anchored in one place for a lifetime.

Plants are stuck. The best they can do is grow toward something, says Courtney Hollender, a former postdoc of Dardicks who now runs her own lab in the Department of Horticulture at Michigan State University in East Lansing. Thats all theyve got; they cant run, they have to adapt to their environment. And theyve developed brilliant ways to do it.

Scientists have a word for the ability to adapt so readily: plasticity. In plants, this feature is both obvious and astounding. Most animals are born in specific shapes then just grow larger, but plants are modular they grow in various iterations of two building blocks: shoots and roots.

It is the first of these where and when a shoot grows or doesnt grow that governs the basic form a tree takes.

Some aspects are hardwired. Leaves emerge in a pattern that is usually fixed throughout the trees life, with structural arrangements that tend to be shared by members of a given plant family. And shoots emerge where leaves meet the stem. So, for example, plants in the maple family, which have leaves set opposite each other, have branches in the same format. Members of the beech family have leaves, and thus branches, that alternate up the stem.

But the interplay between physiology and external forces also plays a large part. Take your standard-issue plant with a main central stem that grows upward and has few side branches. Most plants, from basil to birch, start out this way, a growth habit that probably evolved because it enables them to quickly reach the light more rapidly than the competition. Called apical dominance (the tip of the plant is the apex), this is largely under the purview of the plant hormone indole acetic acid, also known as auxin. Made in the tip, auxin diffuses downward and blocks the growth of side branches.

This is why pinching the tips off of basil or geranium makes them bushy you are removing the source of that bossy auxin, freeing buds on the stems sides from the prohibition and allowing them to grow. (Though auxin is mighty, its not the only player here. Other plant hormones, along with light intensity and access to nutrients, also wield power.)

Another related and less-understood phenomenon occurs in some tree species. Called apical control, it also is imposed by the tip of a tree and probably also by auxin. But rather than operating at the scale of a branch, it commandeers the whole dang tree.

Think of a pine. At the top, theres a pointy tip, then upper branches that tend to reach skyward. Moving down, the branches become more horizontal, growing out more than up. But unlike a basil plant, a pine tree does not become bushy when you lop off the top. Instead, a new bud near the top grows upward, becoming the new leader. Or an existing branch reorients to grow up and become the new dominant tip.

These two principles are always in the back of arborists minds as they work. They have to consider, If we cut a branch here, that bud below is going to break and well just get a branch in basically the same spot, Dardick says. All of their rules of what to prune and where are based on these physiological factors that contribute to tree shape.

Physiology also underpins the plastic responses trees have to more extreme situations they may face. A tree on a high mountain peak or windswept coast must contend with exposure to mechanical forces that could topple and kill it. To survive, such trees become short and stocky, their bent, asymmetric crowns reducing drag and presumably protecting a tree from violent gusts. The driver is the winds very touch a response now called thigmomorphogenesis that has been observed for hundreds of years.

How it works is still unclear, but over the past decade researchers have made some headway. Theyre actively studying force-sensing proteins and processes that may be involved. And recent work suggests an important role for hormones such as jasmonate, which accumulates in all kinds of plants in response to damage and mechanical stress. In experiments with a weedy mustard called Arabidopsis, plants became stunted when researchers bent their leaves back and forth twice a day.Mutants that couldnt make jasmonate, though, grew normally.

Sometimes, wind does more than gust against a tree: It blows the whole tree over, and that tree, if still rooted, must reorient the growth of its branches and buds toward the sky. Avalanches, erosion and landslides deal similar fates. And trees in all sorts of circumstances must grow around obstacles, away from competitors and toward the light. To get these jobs done, trees make a special kind of wood called reaction wood.

Trees may become contorted in challenging physical environments, such as this ridge in the Rocky Mountains. The touch of wind and other forces prompt physiological responses by the plant that yield a shorter, stockier stature, gnarled asymmetric shape and the development of specialized wood. This characteristic tree form is called a krummholz (German for crooked wood).

CREDIT: BRYCE BRADFORD / FLICKR

Hardwoods such as maple, beech, oak and poplar form this tough stuff (in this case called tension wood) on the upper side of their stems. Incredibly, it creates a tensile force thatpullsthe stem upward. If you walk around the woods, you can see that most species, if not all species, have this kind of reaction wood response, says Andrew Groover, a research geneticist with the USDA Forest Services Pacific Southwest Research Station in Davis, California.

The hardwood tree first discerns that it is off-kilter using specialized gravity-sensing cells. Where these cells reside in trees the woody stem? the tip of new shoots? was unknown until Groover and colleagues detected them in woody and soft tissues of poplar, a few years back. The cells contain organelles called statoliths that sink down in the cell and indicate to the plant that its leaning one way or the other. This, in turn, causes that influential auxin to mobilize, triggering the growth of tension wood on the top. Cellulose with a peculiar gelatinous layer is thought to act as the muscle that generates the pulling-up force.

In this experiment, young, potted poplar trees were placed sideways to investigate the plantsgravity-sensing machinery. The poplar in this time-lapse movie, taken over two weeks, responded to being tipped on its side by reorienting its growth upward. The plant hormone auxin is key to this response. Mutants that cannot respond appropriately to auxins signaling instructions do not right themselves this way. (This particular poplar also received a dose of a chemical called gibberellic acid that interacts with auxin, so that scientists could learn more about its role.)

CREDIT: ANDREW GROOVER AND SUZANNE GERTTULA, US FOREST SERVICE, PACIFIC SOUTHWEST RESEARCH STATION DAVIS CA

Much of the knowledge about the architecture of plants is rooted in millennia of human efforts to alter crop shapes to make them more suitable for cultivation, and modern science is now revealing the genetic changes that lie behind these creations. The lessons, it turns out, apply broadly across the plant kingdom, to herbaceous and woody species alike.

It is hard to overstate the importance to human history of some of these plant-shape changes, says plant molecular geneticist Jiayang Li, who details some of their genetic underpinnings in the Annual Review of Plant Biology. A classic example is the transformation of the ancestor of corn (maize) into a key staple crop for much of the world. It arose from a species of the Central American grasses called teosintes bushy plants with many branches. Domestication, among other things, abolished that branching, yielding the single-stalked upright corn we plant today.

Similarly, explains Li, who works at the Chinese Academy of Sciences Institute of Genetics and Developmental Biology, the green revolution of the 20th century ushered in compact, dwarf varieties of wheat and rice. By modifying the height and thickness of the stems of these grasses, breeders developed varieties that could carry more grain without toppling over in wind and rain.

Much of Lis own research has focused on architectural variation in rice, although the work turns out to have implications for the architecture of plants in general, from lowly mosses to towering trees. Like other grasses, rice grows shoots called tillers specialized, grain-bearing branches that emerge from the base. In cultivated rice, the angle at which these tillers grow varies widely: Some varieties are squat and wide-spreading, others have shoots that are more upright. Breeders are interested in altering tiller angle because upright plants can be grown more densely, giving farmers more bang for their acreage.

In a key advance, in 2007, a team including Li reported theyd discovered the genetic cause of the spread-out architecture trait. The scientists named the responsible gene TAC1, short for tiller angle control. A functional TAC1 gene increases rices tiller angle, leading to open, widely branching plants. Mutations in TAC1 lead to the opposite: plants with erect shoots that reach up, instead of out.

That same year, Lis team and a group in Japan both reported another major achievement: finding a long-sought gene behind a curious trait in some rice varieties that gives plant branches a scruffy, lounging look. The trait, known as lazy, had intrigued plant breeders and geneticists since the 1930s, when researchers described its extreme manifestation in corn: The lazy plants grow along the ground, following the unevenness of the surface.

In ordinary rice (left), the hormone auxin helps to tell the plant which direction is up. Auxin transport within the plant goes awry when a gene called LAZY malfunctions, leading to confused plants with sprawling branches (right).

CREDIT: B. WANG ET AL / AR PLANT BIOLOGY 2018

The cause, it turns out, was errors in a gene that normally makes branches shoot straight up. Li and his colleagues surveyed some 30,000 mutant rice plants to pin down that gene, now called LAZY (names of genes, confusingly, often refer to what happens when a gene is mutated and doesnt work, rather than when it is functioning properly). And they provided convincing evidence for an idea batted around for decades that lazy plants have muddled perceptions of gravity and that auxin is centrally involved.

A common test for whether a plants gravity-perception machinery is working is to lay the plant on its side. If it knows up from down, it wont continue to grow sideways, but will start to grow up again, akin to the reaction-wood response of a toppled trees branches. An important step in this reorienting involves auxin pooling on the bottom side of the shoot. But in lazy mutants, proteins that help ferry auxin around the plant are malfunctioning, so instead of shoots growing in the correct direction, theyre prone to casually sprawl about.

Scientists now know that LAZY genes come in multiple versions. Some appear to operate in plant roots, telling them which way is down, probably using similar, auxin-related signals. If those genes are absent or inactive, confused roots grow upward. And though the genes were first found in monocots, a branch of the plant kingdom including rice and corn, researchers now know that LAZY genes exist in numerous plants, including the plums growing in the fruit research station in West Virginia.

A lazy mutant of corn (left) compared with normal corn (right). Such corn mutants were described nearly 100 years ago, but it took 21st century molecular biology to nail down the growth habitscause: genetic malfunctions that meddle with responses to gravity.

CREDIT: T.P. HOWARD III ET AL / PLOS ONE 2014

As our boots crunch along the uneven ground, Dardick points at an errant orchard cat watching our tree tour from a distance. One row of trees stands so upright that a fencepost at the end of it is enough to block the row from view. These regimented trees are pillar peaches, and they are favorites of landscapers (one reason: its easy to get around them with a lawnmower). They also were key to uncovering genes like LAZY and TAC1 at the Shenandoah Valley station.

By comparing ordinary peaches to pillar peaches, and drawing on decades of work by former lead scientist Ralph Scorza, a team of station scientists and others in the US and Germany discovered the cause of the pillar trait: mutations in the peach version of TAC1.

Many of the strange plant architectures under investigation existed as naturally occurring varieties that were developed by breeders for ornamental gardens or orchards; only recently have the genes underlying these forms been identified. Its now known that the upright growth habit of the pillar peach (center), available commercially under the nameCrimson Rocket,results from mutations in a gene that helps plants branch outward.

CREDIT: C. DARDICK

The team also found that LAZY was at work in many of their misfits. Just as with the corn plants described nearly 100 years ago, mutations in LAZY made plums grow topsy-turvy, their branches seeking the soil. Apple trees with LAZY mutations have similarly disoriented roots. And when multiple copies of LAZY genes malfunction in the weed Arabidopsis, its roots grow up, its shoots down.

In the last decade, researchers have found that TAC1 influences branch angle in plums, poplar trees, the grass Miscanthus and Arabidopsis, and it appears to affect leaf angle in corn. But LAZY genes have even deeper roots. Theyre found in all manner of plants, including the evolutionarily older Loblolly pine and even more ancient mosses.

This finding suggests a very old role for LAZY: It may have allowed plants to grow up, literally, when they first colonized land. Plants got their start in water. There, rootless and leafless, they were buoyed, unconcerned with gravity. The transition to land spurred the development of proper roots and stems, and plants then had to figure out up from down. LAZY seems to have allowed plants to orient their above-ground growth away from gravity and up toward the sun.

Scientists think that TAC1 evolved somewhat later, providing a counterpoint to LAZY ensuring that branches dont only grow straight up, but also reach out. Together, these genes laid critical groundwork for the diversity of plant forms we see today, all seeking sustenance in their own ways.

Once you start to grow up as a vascular plant, you need to maximize your resources, you need to capture as much sun as possible, says Hollender, who has been working on yet another gene, called WEEP, that when nonfunctional lends plants a weeping, waterfall-like structure seen here and there in trees of ornamental gardens. (But its probably not responsible for the shape of weeping willow trees.) Modifying your shoot angles is an important adaptive trait for plants that allows them to capture light. Its essential for them to survive.

This kind of research has broad economic implications. Fruit and nut trees bring $25 billion annually in the US alone and there are hefty costs associated with pruning, bending and tying branches; spraying hormones; and the manual labor of picking fruit from an unruly cacophony of limbs. Understanding the genetic controls behind tree architecture could help scientists breed trees that make the whole fruit-farming enterprise more efficient and environmentally friendly.

Orchard systems are not the most sustainable in the world, Dardick says. The idea is, if we can modify tree architecture, if we could reduce their size and limit the amount of area they take up, then we could plant them at higher density and potentially increase their sustainability.

And there may be odder outcomes than friendlier outdoor orchards: In collaboration with NASA, the USDA team is investigating genetic tweaks that might even help bring fruit to space. On that December day, Dardick takes me to a greenhouse tucked in a corner of the lab. In it are plum and apple trees whose shape is so transformed that they look more like the love children of shrubs and vines. This strange growth habit is a side-effect of efforts to breed plants that flower and make fruit sooner and then do so continuously, rather than flowering after growing for several years, and then only in the spring.

The genetic tweaks that sent the trees developmental program into overdrive have also transformed their architecture. In the greenhouse, these precocious trees sprawl, draping lazily along wire trellises, happily flowering and heavy with fruit. Theyre growing almost like tomatoes, Dardick says. So were broaching the concept of, can we bring an orchard indoors?

The strange, vine-like growth of this plum results when a gene controlling the timing of flower development malfunctions. Such unusually shapedtrees may facilitate indoororchards that produce fruit many months of the year.

CREDIT: C. SRINIVASAN

Those ambitions aside, Dardick has his hands full trying to answer numerous basic-science questions about how trees do what they do. Researchers still dont know how different tree species set the angles of their branches going wide like an oak, or arching like an elm. They dont know how trees alter those angles during the course of mature growth, as branches sprout from branches sprouted from branches, until some of them finally point down. Trees are both kindred and foreign to us, their various forms so familiar, but their architectural rules still in so many ways opaque.

I find myself looking at trees all the time now in a new way; they fill space so beautifully and efficiently, Dardick says. They are the biggest organism we have thats visible, thats in our face all the time. But theres so much we dont know.

Read this article:
Bent into shape: The rules of tree form - Knowable Magazine

Read More...

Viral epidemics, public health and universal vaccine against influenza, in international conference Viruses2020 – Mirage News

Monday, February 3rd, 2020

This international conference will gather more than two hundred participants.

Professor Albert Bosch, from the Faculty of Biology of the UB, and the expert Eric O. Freed from the National Cancer Institute (United States).

The Long Road to a Universal Influenza Virus Vaccine is the title of the master conference to be given by the expert Peter Palese, from the School of Medicine at Mount Sinai (United States), in the opening ceremony for the conference Viruses2020 to take place on Wednesday, February 5, at 9 a.m. This international conference will gather more than two hundred participants and is promoted by a committee presided by Professor Albert Bosch, from the Department of Genetics, Microbiology and Statistics of the Faculty of Biology of the UB, and the expert Eric O. Freed from the National Cancer Institute (United States).

During his speech, Peter Palese will talk about the most recent studies on a protein from the surface of influenza hemagglutinin which could lead to the development of a vaccine against influenza, a viral infection that can create annual epidemics with about five million affected people and more than 600,000 deaths worldwide.

As part of this forum, which will take place from February 5 to 7 in the headquarters of Axa auditorium, the experts will show the latest advances in viral pathogenesis, innate immunity, viral replication and the evolution of viruses, among other content. In the 21st Century world, the challenge is to be always ready for the challenges that can come up regarding globalization and climate change, which contribute to the emergence of viral infections, notes Alfred Bosch, president of the Spanish Society of Virology (SEV).

Globalization, public health and viral epidemics

This work can only be based on solid knowledge on the molecular biology of the different viruses, continues Bosch. Regarding coronavirus, it is a fascinating group of viruses from the molecular perspective, which were not thought to be related to any important public health problem. When the SARS, MERS and 2019-nCoV (Wuhan) infectious episodes of coronavirus appeared, the basic knowledge of the scientific community have been determining to enable fast progress in the research on this coronavirus, as relevant as human pathogens.

Regarding the emerging viral infection episodes we should avoid panic and develop tools for diagnosis like in the coronavirus case- in order to establish control systems. Afterwards, we need knowledge on their transmission, reservoirs, etc. and this is the current phase we are in. The next step would be, therefore, to work on therapies, prophylactic therapies like vaccines, or antiviral ones.

See original here:
Viral epidemics, public health and universal vaccine against influenza, in international conference Viruses2020 - Mirage News

Read More...

David Hogness, Revolutionary of 20th Century Genetics, Dies – The Scientist

Wednesday, January 22nd, 2020

David Hogness

courtesy stanford medicine

David Hogness, a biochemist, geneticist, and developmental biologist at Stanford University, died at his home on December 24. He was 94 years old.

Hogness is well known for a series of experiments during the 1970s and 1980s that were instrumental in launching both molecular genetics and genomics, according to a university statement.

His lab brought molecular biology to Drosophila, discovered the first core promotor element in eukaryotes, cloned the Hox genes, studied the basis of steroid hormone signaling, the list goes on and on. He was a giant, says biologist Mark Peifer of the University of North Carolina in a tweet.

Hogness was born in Oakland, California, on November 17, 1925, and grew up in Chicago. In 1949, he received his bachelors degree in chemistry from Caltech, where he also earned his PhD in biology and chemistry in 1952.

While a faculty member at Washington University in St. Louis, Hogness studied bacteriophage lambda and created the first physical maps of genes along DNA, according to the statement. He joined Stanfords newly formed biochemistry department in 1959, and during a sabbatical in 1968, shifted his focus to Drosophila.

In a 1972 grant proposal, Hogness described the concept of chromosomal walkingnow known as positional cloninga technological breakthrough that many consider to be the founding of genomics, according to Stanfords statement.Hognesss 1975 paper published in PNAS detailed colony hybridization, a novel method of isolating cloned DNA. Three years later, Hogness discovered the Goldberg-Hogness box, now called the TATA box, a non-coding promoter sequence where transcription is initiated in archaea and eukaryotes (prokaryotes have a homolog called the Pribnow box). Another landmark study published in the early 1980s demonstrated the ability to clone the gene underlying any genetic trait, and simultaneously proved there were genes specifically devoted to regulating normal development, says Richard Lifton, the president of Rockefeller University and a former student of Hogness, in the press release. Its one of the great papers in the history of biology.

Daves genius was to realize that the recombinant DNA technologies newly developed at Stanford, which allowed researchers to isolate and replicate to very high copy numbers distinct segments of DNA, could be used to map the locations of the DNA segments to specific bands on the polytene chromosomes, developmental biologist Philip Beachy says in the statement.

Hognesss awards include the March of Dimes Prize in Developmental Biology in 1997, the Lifetime Achievement Award of the Society for Developmental Biology in 2002, the Thomas Hunt Morgan Medal in 2003, and the Warren Alpert Foundation Prize in 2013.

Hogness is survived by his sons.

Amy Schleunes is an intern atThe Scientist. Email her ataschleunes@the-scientist.com.

Read more:
David Hogness, Revolutionary of 20th Century Genetics, Dies - The Scientist

Read More...

Page 22«..10..21222324..30..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick